4th World Congress on ADHD
From Childhood to Adult Disease

6 – 9 June 2013
Milan Congress Centre (MIC)
Milan | Italy

www.adhd-congress.org

FINAL PROGRAMME
The omega-3 & -6 product with proven clinical efficacy\(^1\)\(^-\)\(^2\)


www.equazen.com
Welcome Address ......................................................... 4
Organization .................................................................... 5
Acknowledgements ............................................................ 5
Committees ......................................................................... 6
World Federation of ADHD .................................................. 7
General Information
Congress Venue ................................................................... 8
Access Map to Congress Venue ........................................... 8
Congress Registration Counter ........................................... 9
Registration Fees .................................................................. 9
Certificate of Attendance .................................................... 9
Name Badges ....................................................................... 10
Congress Language ............................................................ 10
EACCME – Continuing Medical Education .......................... 10
Publications for Proceedings .............................................. 10
Internet Centre .................................................................... 10
Congress Information System ............................................. 10
WLAN/WIFI ...................................................................... 10
Congress APP ..................................................................... 10
Technical Exhibition .......................................................... 11
Poster Exhibition ............................................................... 11
Awards ................................................................................. 11
Speakers Centre .................................................................. 11
Restaurants ......................................................................... 11
Coffee Breaks and Lunch .................................................... 12
Cloakroom ......................................................................... 12
Bank .................................................................................. 12
Currency ............................................................................. 12
Electricity ............................................................................ 12
Lost and Found .................................................................... 12
Mobile Phones ..................................................................... 12
Programme Changes .......................................................... 12
Climate ............................................................................... 12
Press .................................................................................. 12
Insurance ............................................................................ 12
Registration Conditions ..................................................... 12
Official Italian Agency ......................................................... 12
Public Transport ................................................................... 13
Car Park .............................................................................. 13
Taxis .................................................................................. 13
Format Descriptions .......................................................... 15
Opening Ceremony ............................................................. 16
Patients Day ......................................................................... 16
Programme Overview .......................................................... 17
Scientific Programme
Thursday, 6 June 2013 ......................................................... 21
Friday, 7 June 2013 ............................................................... 23
Saturday, 8 June 2013 .......................................................... 38
Sunday, 9 June 2013 ............................................................. 54
Educational Goals .................................................................. 55
Satellite Symposia ............................................................... 60
List of Exhibitors and Map .................................................... 62
List of Chairpersons and Presenters ...................................... 63
CONGRESS APP
Get the 4th World Congress on ADHD 2013 APP for your smart phone now and experience the congress at your fingertips! Quickly find your way through the most up-to-date congress schedule. Stop carrying around piles of paper. Just take the congress with you, wherever and whenever you want! The APP is completely free and provides iPhone/iPad, Android Smartphone users at the 4th World congress on ADHD 2013 in Milan.

The ADHD 2013 APP is powered by GLOBIT’s acclaimed CONGRESS MOBILE® software.

Further information is given at
www.adhd-congress.org/mobile
Dear colleagues and friends,

In the name of the World Federation of ADHD, it is our pleasure to welcome you here in Milan to the 4th World Congress on ADHD: From Childhood to Adult Disease. We are confident that this will be a very enjoyable and highly informative event. The key themes addressed will be: The costs and benefits of ADHD, developmental aspects of classification and co-morbidity; psychosocial and neurobiological aspects related to aetiology, the latest updates on genetics and neuroimaging, new findings in the psychotherapeutic and psychopharmacological treatment approaches, and features of life quality.

After the incredible success of the Berlin meeting two years ago – Milan is the ideal setting to elucidate and discuss the current advances in basic science and clinical research, contributing to our understanding of ADHD as a lifespan disorder.

Milan was the capital of the Western Roman Empire and boasts a unique artistic heritage. The Ancient Romans called Milan “Mediolanum” since it was in the centre of the great connecting roads of the time. Today, Milan is still a meeting place and nowadays a modern global city.

We are delighted to welcome internationally renowned speakers to address the exciting and important topic of ADHD in Plenary Symposia, Hot Topic Symposia, a Pro-Con Debate, a Video Session, Educational Seminars and Meet-the-Experts Sessions. We are privileged to have gained an impressive number of speakers, with a wealth of global experience and expertise in ADHD research, sharing their work with us here at this conference. In addition to the main conference programme, young talents will present their new ideas in Young Scientist Award Sessions. We are proud to have over 400 posters, which will be presented in 37 Guided Poster Tours, demonstrating the large volume of research activity and evidence-based clinical practise in this field. We would like to encourage you to not only view these selected posters, but to also engage in an active discussion and exchange of ideas with our young colleagues.

Please, be welcome to our congress and the city of Milan to combine hard work and the enjoyment of social and cultural highlights, to refresh old friendships or to create new ones as well as fruitful collaborations. But most of all, do not miss the unique opportunity to exchange scientific knowledge, which is the driving force of the World Federation of ADHD and our profession.

Thank you very much for your participation and valuable contribution.

Sincerely yours

Prof. Luis A. Rohde
Congress President
President World Federation of ADHD

Prof. Manfred Gerlach
Chairman Scientific Programme Committee
ORGANIZATION

CONGRESS PRESIDENT

Prof. Luis A. Rohde
Federal University of Rio Grande do Sul
90040-060 Porto Alegre, Brazil
Email: adhd2013@cpo-hanser.de

CHAIR SCIENTIFIC COMMITTEE

Prof. Manfred Gerlach
University of Würzburg
97080 Würzburg, Germany
Email: adhd2013@cpo-hanser.de

CONGRESS VENUE

MIC Milano Congressi
Milan Congress Centre
Entrance No. 14
Via Gattamelata 5
20149 Milan, Italy

ORGANIZER

World Federation of ADHD
Global Head Office
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49 – 40 – 670 88 20
Fax: +49 – 40 – 670 32 83
Email: adhd@cpo-hanser.de

CONGRESS AND EXHIBITION OFFICE

Hamburg Office
Hanser & Co GmbH
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49 – 40 – 670 88 20
Fax: +49 – 40 – 670 32 83
Email: adhd2013@cpo-hanser.de

ACKNOWLEDGEMENTS

The organizers of the 4th World Congress on ADHD gratefully acknowledge the support of the following companies (as per May 2013):

PRINCIPLE SPONSOR

Shire

MAJOR SPONSOR

Eli Lilly and Company
COMMITTEES

SCIENTIFIC PROGRAMME COMMITTEE

Chair: M. Gerlach, Germany

P. Asherson, United Kingdom
T. Banaschewski, Germany
J. Buitelaar, The Netherlands
F. X. Castellanos, USA
S. C. Cho, Republic of Korea
D. Coghill, United Kingdom
J. Deckert, Germany
M. Döpfner, Germany
S. Durston, The Netherlands
S. Faraone, USA
A. Fossati, Italy
C. Freitag, Germany
R. R. Gainetdinov, USA
L. Greenhill, USA
D. A. Hay, Australia
J. Hebebrand, Germany
B. Herpertz-Dahlmann, Germany
S. Kasper, Austria
R. Klein, USA
S. Kooij, The Netherlands
C. J. Kratochvil, USA
K. Lange, Germany
J. O. Larsson, Sweden
K.-P. Lesch, Germany
A. Miranda, Spain
M. Muenke, USA
O. O. Omigbodun, Nigeria
H. Ozawa, Japan
A. Philipsen, Germany
F. W. Reimherr, USA
H. Remschmidt, Germany
P. Riederer, Germany
M. Rösler, Germany
L. A. Rohde, Brazil
A. Rothenberger, Germany
K. Rubia, United Kingdom
P.-A. Rydelius, Sweden
T. Saito, Japan
A. Seif El Din, Egypt
S. Shirataki, Japan
E. Sonuga-Barke, United Kingdom
C. Soutullo, Spain
R.-D. Stieglitz, Switzerland
Y. Taneli, Turkey
R. Tannock, Canada
E. Taylor, United Kingdom
J. Thome, Germany
T. Torgersen, Norway
O. Tucha, The Netherlands
A. Vetro, Hungary
R. Vermeiren, Belgium
S. Walitza, Switzerland
A. Warnke, Germany
M. Weiss, Canada
T. E. Wilens, USA
Y. Zheng, China
A. Zuddas, Italy

LOCAL ORGANIZING COMMITTEE

Chairs: Stefano Pallanti, Firenze
Alessandro Zuddas, Cagliari

Alfredo Carlo Altamura, Milan
Marco Battaglia, Milan
Guiseppe Chiarenza, Milan
Andreas Conca, Bolzano
Andrea Fossati, Milan
In August 2008, the World Federation of ADHD (Attention Deficit Hyperactivity Disorder) and allied disorders was founded in Zurich, Switzerland. Prof. Dr. Andreas Warnke, Director of the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the University of Würzburg, Germany was officially nominated the first president of this non-profit organisation.

ADHD is a highly heritable childhood-onset psychiatric condition which is characterized by age-inappropriate levels of the core symptoms inattention, hyperactivity and impulsivity. The disorder affects about 5% of children worldwide. Recent scientific studies in ADHD reveal biological underpinnings such as multiple genetic factors, ADHD-related differences in brain structure and function, as well as changes in neurotransmitter components within the basal ganglia thalamocortical neurocircuitries. The purpose of the World Federation of ADHD and allied disorders is to support and promote clinical studies, scientific projects and training programmes in the field of ADHD and related disorders worldwide, as well as to enhance the exchange of information between scientists, physicians, health experts, ADHD lay organisations, and the public. The website of the federation www.adhd-federation.org presents the latest abstracts in the field of ADHD updated on a monthly basis and provides regular live chats for exchanging and discussing important scientific issues.

As major tool of the World Federation to achieve these goals, this will be the fourth time the World Congress on ADHD takes place.

World Federation of ADHD, Global Head Office
CPO HANSD SERVICE
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49 – 40 – 670 88 20
Fax: +49 – 40 – 670 32 83
Email: adhd@cpo-hanser.de

General Assembly
6 June 2013 | 14:00-15:00 | Hall Yellow 2

BECOME A MEMBER NOW!

Advantages
- Substantially reduced registration fees for World Congress of ADHD congresses in Milan 2013 and Glasgow 2015
- Access to the latest Abstract Reviews
  A selection of the latest and most important abstract issues in seven different categories will be prepared for all members. One of the most efficient way to be updated!
- Access to a regular Hot Topic Review
- Access to the Springer Journal Link of ADHD
  Benefit from a free access to the online journal of the ADHD Attention Deficit and Hyperactivity Disorders and review latest results
- Networking with colleagues worldwide
- Reasonable annual membership fee EUR 50

Visit us at www.adhd-federation.org
GENERAL INFORMATION

CONGRESS VENUE

MIC Milano Congressi
Milan Congress Centre
Entrance No. 14
Via Gattamelata 5
20149 Milan, Italy

ACCESS TO MIC CONGRESSI/FIERA MILANO

Access to MIC Congressi / Fiera Milano

- From station: Lotto Fiera Milano City
- Congress Entrance: Gate 14

MIC Congressi/Fiera Milano
1st floor

MIC Congressi/Fiera Milano
2nd floor: Room Silver

MIC Congressi/Fiera Milano
South Wing: Auditorium
connected via 2nd floor Room Silver
GENERAL INFORMATION

CONGRESS REGISTRATION COUNTER

All congress materials and documentation will be available from the congress registration counter located at the 1st floor entrance North Hall B, Milan Convention Center.

Opening Hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 6 June 2013</td>
<td>12:00 – 19:30</td>
</tr>
<tr>
<td>Friday, 7 June 2013</td>
<td>07:15 – 18:00</td>
</tr>
<tr>
<td>Saturday, 8 June 2013</td>
<td>07:15 – 18:00</td>
</tr>
<tr>
<td>Sunday, 9 June 2013</td>
<td>07:30 – 13:00</td>
</tr>
</tbody>
</table>

During these opening hours the congress counter can be reached at Phone: +39 – 02 – 872 550 36

The congress counter will be divided into the following sections:

On-site-registration
On-site registration for the congress.

Pre-registration paid
Participants who have already registered and paid for the congress will receive their documents here.

Pre-registration unpaid
Participants who have already registered for the congress, but not paid yet, will receive their documents here.

Information, hotels and tours
Assistance for the reservation of hotel rooms or tours in Milan will be provided.

The staff of the information counter will be pleased to provide you with information about the congress, the congress centre and the city of Milan.

Your World Federation membership fee can be paid at the on-site registration and the pre-registration unpaid, too.

REGISTRATION FEES

<table>
<thead>
<tr>
<th>Registration and Payment</th>
<th>from 3 April 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non member from Countries A¹</td>
<td>EUR 500</td>
</tr>
<tr>
<td>Non member from Countries B¹</td>
<td>EUR 400</td>
</tr>
<tr>
<td>Member World Federation of ADHD from Countries A¹</td>
<td>EUR 450</td>
</tr>
<tr>
<td>Member World Federation of ADHD from Countries B¹</td>
<td>EUR 350</td>
</tr>
<tr>
<td>Students and persons under 35 years*</td>
<td>EUR 350</td>
</tr>
<tr>
<td>Educational Seminars**</td>
<td>EUR 30</td>
</tr>
<tr>
<td>Meet the Expert-Sessions**</td>
<td>EUR 30</td>
</tr>
</tbody>
</table>

¹ For list of countries A and B, please check the congress website.
* A copy of the passport and student identity card is necessary.
** Only valid in combination with the congress registration fee.

Registration fee for the participants includes:
▶ Admission to all scientific sessions
▶ Admission to poster and technical exhibition
▶ Conference materials (delegate bag, final programme, abstract book, etc.)
▶ Admission to the Opening Ceremony and Welcome Reception on Thursday, 6 June 2013
▶ Coffee breaks from Friday to Sunday and lunch snacks on Friday and Saturday

On-site registration
On-site registration will be processed on a first-come, first-served basis. Priority will be given to pre-registered delegates. Depending on the number of on-site registered delegates, availability of congress bags may be limited.

CERTIFICATE OF ATTENDANCE

Please hand in your evaluation form at the counter for a certificate of attendance.
GENERAL INFORMATION

NAME BADGES

All participants are requested to wear their name badge at all times during the congress. The colours of the name badges have the following significance:

Delegate: blue
Exhibitor: green

CONGRESS LANGUAGE

The congress language is English. Simultaneous translations will not be provided.

EACCME – CONTINUING MEDICAL EDUCATION

The 4th World congress on ADHD is accredited by the European Accreditation Council for Continuing Education in Brussels (EACCME), an institution of the UEMS, to provide EACCME credits for the attendance at the scientific sessions of the core programme as well as for the educational seminars. Please hand in the evaluation form you find enclosed in your congress documents at the registration counter.

The 4th World Congress on ADHD is designated for a maximum of 18 CME credit points of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Please hand in the evaluation form enclosed in the congress bag to receive a printed copy of the accreditation certificate.

PUBLICATIONS FOR PROCEEDINGS

The organizer of the congress retains the right to publish all material presented at the congress in any congress publication.

INTERNET CENTRE

Internet terminals are available to all delegates in the exhibition area on the 1st floor Hall B. The Internet Centre is accessible according to the opening hours of the exhibition.

CONGRESS INFORMATION SYSTEM

CO CONGRESS ONLINE®

www.adhd-congress.org

Participants can benefit from the web based ADHD Congress Information System CO CONGRESS ONLINE® on-site. The ADHD Congress Information System provides information on:

- Updated scientific programme
- Programme by day
- Programme by formats with accepted abstracts of chairpersons and speakers
- Programme search
- List of participants (who is who)
- List of exhibitors
- General congress information
- Private mail box

WLAN/WIFI

Free WLAN access is available in Hall B.
Network: ADHD congress

CONGRESS APP

Get the 4th World Congress on ADHD 2013 APP for your smart phone now and experience the congress at your fingertips! Quickly find your way through the most up-to-date congress schedule. Stop carrying around piles of paper. Just take the congress with you, wherever and whenever you want! The APP is completely free and provides iPhone/iPad, Android Smartphone users at the 4th World Congress on ADHD 2013 in Milan.

The ADHD 2013 APP is powered by GLOBIT’s acclaimed CONGRESS MOBILE® software.

Further information is given at www.adhd-congress.org/mobile
TECHNICAL EXHIBITION

The 4th World Congress on ADHD will be accompanied by a technical exhibition taking place 1st floor of Hall B.

Opening hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 6 June 2013</td>
<td>15:00 – 21:00</td>
</tr>
<tr>
<td>Friday, 7 June 2013</td>
<td>09:00 – 18:00</td>
</tr>
<tr>
<td>Saturday, 8 June 2013</td>
<td>09:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, 9 June 2013</td>
<td>09:00 – 13:00</td>
</tr>
</tbody>
</table>

POSTER EXHIBITION

The poster exhibition of the 4th World Congress on ADHD is located in hall B close to the technical exhibition. Posters are allocated to 37 guided poster tours (P-01 to P-37). They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all participants according to the opening time of the technical exhibition:

Guided poster tours will take place:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, 7 June 2013</td>
<td>15:00 – 16:00</td>
</tr>
<tr>
<td>Saturday, 8 June 2013</td>
<td>15:00 – 16:00</td>
</tr>
</tbody>
</table>

The guided posters tours will be chaired by renowned specialists. Interested participants can meet the authors for discussions of their poster presentation during the time of the poster tour.

Set up times for posters

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 6 June 2013</td>
<td>12:00 – 19:00</td>
</tr>
<tr>
<td>Dismantling: Sunday, 9 June 2013</td>
<td>11:00 – 13:00</td>
</tr>
</tbody>
</table>

Posters which have not been removed within the indicated time schedule will be removed. The poster size is 120 cm high and 90 cm wide (Portrait format).

AWARDS

Scientists have been encouraged to hand in their abstracts and apply for the following award:

Young Scientists Award

Young Scientists Sessions aim at encouraging young scientists to attend this interdisciplinary congress in the field of ADHD. The sessions will be composed of 20 minutes lectures. Eight young scientists’ abstracts have been chosen by the scientific committee out of 200 applications for two sessions à four presenters. The sessions will be chaired by recognized experts for the featured topic. Speakers are requested to show via copy of their ID that they are younger than 40 years of age. The winners will receive a young scientist award of EUR 300 each.

POSTER AWARDS

All posters will be evaluated on site and the best of each poster tour will be displayed on separate poster walls after the tours. On Sunday, 9 June 2013, the best six posters will be selected out of all poster tours by the poster prize committee. Members of the poster prize committee are: E. Grünblatt, Switzerland; A. Kutzelnigg, Austria; G. Polanczyk, Brazil; T. Renner, Germany; L. Salerno, Italy (as per 10 May 2013). Best posters will be awarded during the closing ceremony on the last congress day.

SPEAKERS CENTRE

The speakers centre is located on the 1st floor Foyer close to the entrance of the technical exhibition. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their presentation but at the latest 90 minutes prior to the presentation. The presentation will be transferred to the central congress server and will be available afterwards on a special congress notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook. Several PC working stations are provided in the speakers centre where speakers can also work on their charts in a quiet area. Technical staff will be glad to assist.

operated by Estensis GmbH
the Conference Company

Opening hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 6 June 2013</td>
<td>12:00 – 19:00</td>
</tr>
<tr>
<td>Friday, 7 June 2013</td>
<td>07:15 – 17:00</td>
</tr>
<tr>
<td>Saturday, 8 June 2013</td>
<td>07:15 – 17:00</td>
</tr>
<tr>
<td>Sunday, 9 June 2013</td>
<td>07:30 – 12:30</td>
</tr>
</tbody>
</table>

RESTAURANTS

Some restaurants and bars are in walking distance of the congress venue and a snack bar can be found adjacent to the exhibition area of the Milano Convention Center.
GenerAl InFORMATIon

COFFEE BREAKS AND LUNCH

Coffee and tea are served during the morning and afternoon coffee breaks from Friday morning, 7 June to Sunday 9 June 2013 free of charge to all registered participants in the exhibition area. A healthy pasta lunch buffet will be served in the exhibition area on Friday and Saturday to all registered delegates.

CLOAKROOM

A cloakroom is available on the ground floor. You can also store your luggage there.
Prices: Coat: EUR 2, luggage: EUR 3

BANK

Several ATM machines are located a few meters away from the congress centre entrance in the streets.

CURRENCY

The official Italian currency is Euro. Exchange of foreign currency is available at Milan Airport and at most hotels, banks and exchange offices throughout the city.

ELECTRICITY

Italy uses a 230 volt 50 Hz system. Sockets have the European standard and plugs are two-prong grounded.

LOST AND FOUND

A lost and found service is available at the registration counter of the congress.

MOBILE PHONES

Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions in the meeting rooms.

PROGRAMME CHANGES

The organisers cannot assume liability for any changes in the congress programme due to external or unforeseen circumstances. In the event of cancellation by speakers or other changes in the main programme, no full or partial refund of the registration fee can be made.

CLIMATE

The climate of Milan is mediterranean, but like any large urban metropolis, buildings and human affect the local micro climate. In the case of Milan this makes the weather rather more extreme. In June the temperature is between 15°C (59°F) and 26°C (79°F).

PRESS

Journalists should bring their press ID and register at the registration counter.

INSURANCE

The congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is recommended and has to be purchased in your country of origin.

REGISTRATION CONDITIONS

The general conditions for the congress registration including payment and cancellation of the World Congress on ADHD are published on the congress website: www.adhd-congress.org

OFFICIAL ITALIAN AGENCY

AIM GROUP – AIM Education s.r.l.
Via G. Ripamonti, 129
20141 Milan, Italy
Phone: +39 – 02 – 56601 259
Email: adhd2013.hotel@aimgroup.eu

AIM Group is the official Italian agency which is authorised to deal with Italian Health Authorities.
How to get from the AIRPORT TO THE CONGRESS VENUE (MIC)

Milan has two airports, Malpensa airport is located approximately 50km north-west of Milan, Linate airport is located close to the city center.

From Malpensa airport:
Regular coach shuttles are connecting the airport with the city center and stop directly at Milano Congress Center. Duration depending on traffic 60 – 90 minutes. Some taxi companies offer a fixed price of EUR 90 from the airport to the city centre.

A regular train service is available to Milano Centrale and Cadorna Station 4 times per hour and highly recommended. Ticket price for the train: EUR 10 – 15.

Taxis are available at the train stations for reasonable prices to the Milano Congress Center. Duration depending on traffic 30 – 60 minutes.

From Linate airport:
Linate airport is located close to the city center. A regular public bus service to Milano Centrale is available as well as taxi services. Some taxi companies offer a fixed price of EUR 55 from the airport to the city centre.

PUBLIC TRANSPORT to Milano Congress Center within the city:

Underground Red Line 1, Green Line 2:
Get off at the Cadorna stop, exit the subway and go to the railroad station above: Take the first train departing and get off at the Domodossola stop – just 600 m from Centro Congressi.

Underground Yellow Line 3:
Get off at Duomo, switch to the Red Line 1 (RHO Fiera Milano direction), get off at the Cadorna stop, exit the subway and go to the railroad station above: Take the first train departing and get off at the Domodossola stop – just 600 m from Centro Congressi

Bus no. 78: Get off at Colleoni/Gattamelata
Tram no. 27: Get off at Piazza 6 Febbraio

Daytickets are available for public transportation for EUR 7 per day and can be purchased at the ticket machines as well as at bars, tobacconists, stationers and newspaper stands.

CAR PARK

Parking space is available next to the Congress Center and participants arriving by car are advised to use these facilities. Parking fees are not included in the registration fee.

TAXIS

Taxis are available upon demand in front of the main entrance. For taxi prebookings Yellow taxi, phone: +39 – 02 – 69 69 is recommended.
World Federation of ADHD
Attention Deficit Hyperactivity Disorder

President Prof. Luis A. Rohde, Brazil
4th World Congress on ADHD
From Childhood to Adult Disease

SAVE THE DATE
we look forward meeting you at the
5th World Congress on ADHD
From Childhood to Adult Disorder
28 – 31 May 2015, Glasgow, Scotland

- Exchanging information on developments
- Advance the clinical and basic research
- Scientific, scholarly and educational training
- Collaboration with other related professional and lay organisations

www.adhd-congress.org

Global Head Office and
Congress and Exhibition Office
CPO HANSEN SERVICE
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49 – 40 – 670 882 0
Fax: +49 – 40 – 670 32 83
Email: adhd@cpo-hanser.de
**FORMAT DESCRIPTIONS**

**PLENARY SESSIONS (PL)**

**Duration:** 90/120 min.

Plenary sessions will feature authoritative scientific updates on a comprehensive range of topics. Each daily session is composed of three to four 30-minute lectures presented by international leaders in the field of ADHD. After the talk there will be no discussion.

**HOT TOPIC SYMPOSIA (HT)**

**Duration:** 90 min.

Hot topic symposia will feature comprehensive reviews of the most recent research results as well as practical issues in the field of ADHD. Each 90-minute symposium, presented by internationally recognized clinicians and neuroscientists, contains a theme of topical interest and is composed of three or four lectures, with a maximum of 20 minutes. After the talks there will be short discussions.

**EDUCATIONAL SEMINARS (ES)**

**Duration:** 45 min.

Educational seminars are designed to be informal and interactive and will feature an update on clinical relevant topics. Each 45-minute seminar is composed of one, respectively two lectures and is followed by a discussion. To facilitate coordination, attendance is limited. Therefore it is recommendable to book the ticket together with the congress registration online or to check ticket availability on site at the registration counter. Tickets will be handled on a ‘first-come, first-served’ basis.

Registration fee per session: EUR 30.

Only valid in combination with the congress registration fee.

**GUIDED POSTER TOURS (P)**

**Duration:** 60 min.

All accepted posters will be presented during guided poster tours. The posters will be displayed in the poster exhibition hall. The lead or senior authors should be present during the one-hour presentation. The presenting author has to be registered.

**VIDEO SESSION (VS)**

**Duration:** 90 min.

The video session will last 90 minutes. Two or three experts in the field of neurology and psychiatry will present cases of neuropsychiatric diseases and will discuss the given diagnosis with participants.

**YOUNG SCIENTISTS’ SESSION (YS)**

**Duration:** 90 min.

Young scientists' sessions are specifically aimed at young scientists in the field of ADHD. Selected by the Scientific Programme Committee eight young scientists have the possibility to present their findings. Chaired by recognized experts in the featured topic, these interdisciplinary sessions are composed of 20-minute lectures, followed by short discussions.

**MEET THE EXPERT SESSIONS (ME)**

**Duration:** 45 min.

Meet the expert sessions have been specifically designed to provide an informal atmosphere where doctors and scientists can interact with internationally renowned experts in the field of ADHD. The sessions are especially suitable for the exchange of knowledge and aim at first-hand learning about the latest clinical (practical) and scientific advancements. Meet the Expert Sessions are open to all participants but tickets are handled strictly on a ‘first-come, first-served’ basis.

Registration fee per session: EUR 30.

Only valid in combination with the congress registration fee.

**PRO-CON DEBATE (PCD)**

**Duration:** 90 min.

Two experts will debate the pros and cons of an up-to-date topic within the field of ADHD. A moderator will lead the discussion.

**INDUSTRY SUPPORTED SYMPOSIA**

**Duration:** 60 – 120 min.

Satellite symposia will be organised by pharmaceutical companies and are open to all congress delegates.
OPENING CEREMONY/PATIENTS DAY

Thursday, 6 June 2013  19:00  Silver Room, MIC Milan

Welcome to Milan
Welcome Address by the Congress President
Professor L. A. Rohde, Brazil
and
the Local Organizing Committee

Introduction to the 4th World Congress
Scientific highlights and key facts by
Professor J. Thome, Germany

ADHD Awareness Day
Representatives from different ADHD associations will give the
World Federation of ADHD the petition for the WHO.
Moderator: Professor L. A. Rohde, Brazil

Milan Opera Tenors:
Recondite armonie
Giacomo Puccini from Tosca
Questa o quella
Giuseppe Verdi from Rigoletto
La donna è mobile
Giuseppe Verdi from Rigoletto
E lucevan le stelle
Giacomo Puccini from Tosca
Brindisi
Giuseppe Verdi from Traviata

Welcome Reception and Get-Together
At the end of the Opening Ceremony all participants are invited
to join the Welcome Reception in the exhibition area Hall B.
Light snacks and beverages will be provided.

PATIENTS DAY  I  Friday, 7 June 2013

As in the former years, a patients day will take place during the congress. This time, the patients day will be
held on Friday, 7 June 2013, from 08:30 – 18:00. Registration can be done online referente.lombardia@aifa.it,
admission is free of charge.

The venue
Cinema Orizzonte
Piazzale Damiano Chiesa
20125 Milan

The venue is within walking distance to the congress center.
## Programme Overview – Thursday, 6 June 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Silver Room</th>
<th>Red Room</th>
<th>Yellow 2 Room</th>
<th>Yellow 3 Room</th>
<th>Blue 1 Room</th>
<th>Blue 2 Room</th>
<th>Foyer and Hall B</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>VS-01</td>
<td>HT-01</td>
<td></td>
<td>HT-02</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neuro-psychiatric movement disorders in children, adolescents and adults</td>
<td>Research consortia present new findings</td>
<td>Symposium on the results of the International ADHD in substance use disorders prevalence (IASP) study; ...</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>VS-01</td>
<td>HT-01</td>
<td></td>
<td>HT-02</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neuro-psychiatric movement disorders in children, adolescents and adults</td>
<td>Research consortia present new findings</td>
<td>Symposium on the results of the International ADHD in substance use disorders prevalence (IASP) study; ...</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>HT-03</td>
<td>YS-62</td>
<td></td>
<td>HT-04</td>
<td>HT-05</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Effects and mechanisms of psychotherapy in the treatment of ADHD in children and adults</td>
<td>Young Scientist Award Session</td>
<td>Research on ADHD in Asia and Australia</td>
<td>Risk pathways and ADHD prodromes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>Opening Ceremony and Welcome Address</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30–21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Welcome Reception in the exhibition area Hall B</td>
</tr>
</tbody>
</table>

### Abbreviations
- **PL**: Plenary Session
- **SA**: Satellite Symposium
- **ES**: Educational Seminar
- **ME**: Meet the Experts-Session
- **HT**: Hot Topic Symposium
- **VS**: Video Session
- **YS**: Young Scientist Session
- **PCD**: Pro-Con Debate
- **P**: Guided Poster Tour
## FRIDAY, 7 JUNE 2013 – PROGRAMME OVERVIEW

<table>
<thead>
<tr>
<th>Time</th>
<th>Silver Room</th>
<th>Red Room</th>
<th>Yellow 1 Room</th>
<th>Yellow 2 Room</th>
<th>Yellow 3 Room</th>
<th>Blue 1 Room</th>
<th>Blue 2 Room</th>
<th>Foyer and Hall B</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>ES-01</td>
<td>ME-01</td>
<td>ME-03</td>
<td>ES-02</td>
<td>ES-03</td>
<td>ME-03</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Organisation and carrying out of parent...</td>
<td>Diagnosis of ADHD</td>
<td>ADHD over the lifetime</td>
<td>How do differ ADHD from bipolar and...</td>
<td>How to do best medication in adult ADHD?</td>
<td>Pharmacological treatment of ADHD...</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>PL-01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Costs and benefits of ADHD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **PL-01** Costs and benefits of ADHD
- **PL-02** Approaches to the subtyping of ADHD
- **ES-01** Organisation and carrying out of parent...
- **ME-01** Diagnosis of ADHD
- **ME-03** ADHD over the lifetime
- **ES-02** How do differ ADHD from bipolar and...
- **ES-03** How to do best medication in adult ADHD?
- **ME-03** Pharmacological treatment of ADHD...

**Coffee Break**

**Lunch Break**

**Auditorium Southwing**

- **SA-01** Elvanse (lisdexamfetamine dimesylate): A new option in ADHD treatment (Shire)

**P-01 – P-05 / P-07 – P20 Guided Poster Tours**

**Coffee Break**

**HT-06** Is psychostimulant treatment of ADHD harmful for the patient?
**HT-07** ADHD – The subjective burden of disease
**YS-63** Young Scientist Award Session
**HT-08** The role of sleep problems and circadian Clock genes in ADHD
**HT-09** Personality disorder in adult ADHD
**HT-10** Vigilance regulation model of ADHD and affective disorders
# Programme Overview – Saturday, 8 June 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Silver Room</th>
<th>Red Room</th>
<th>Yellow 1 Room</th>
<th>Yellow 2 Room</th>
<th>Yellow 3 Room</th>
<th>Blue 1 Room</th>
<th>Blue 2 Room</th>
<th>Foyer and Hall B</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00</td>
<td>ME-04</td>
<td>Predictors of persistent ADHD</td>
<td>ME-05</td>
<td>Neurobiology of ADHD</td>
<td>ES-04</td>
<td>How to do neurofeedback in ADHD?</td>
<td>ES-05</td>
<td>Comorbid disorders or attention deficit-spectrum?</td>
<td>ES-06 Assessment of adult ADHD</td>
</tr>
<tr>
<td>08:00</td>
<td>PL-03</td>
<td>What is next in ADHD?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>PL-03</td>
<td>What is next in ADHD?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>PL-03</td>
<td>What is next in ADHD?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>PCD</td>
<td>Is ADHD a valid diagnosis?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>SA-02</td>
<td>Treatment of ADHD in children and adolescents:... (Eli Lilly and Co.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>SA-03</td>
<td>ADHD: Continuity and consistency of care (Novartis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>HT-11</td>
<td>Approaches to ADHD treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>HT-12</td>
<td>The role of ADHD in forensic psychiatry</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>HT-13</td>
<td>ADHD research in Italy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>HT-14</td>
<td>The relevance of iron in the pathogenesis of ADHD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>HT-15</td>
<td>Brain mechanisms of ADHD interventions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Coffee Break

Technical Exhibition and Poster Exhibition 09:00 – 18:00

Guided Poster Tours in the Exhibition Hall B
SUNDAY, 9 JUNE 2013 – PROGRAMME OVERVIEW

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Silver Room</th>
<th>Red Room</th>
<th>Yellow 1 Room</th>
<th>Yellow 2 Room</th>
<th>Yellow 3 Room</th>
<th>Blue 1 Room</th>
<th>Blue 2 Room</th>
<th>Foyer and Hall B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td></td>
<td></td>
<td></td>
<td>ES-07</td>
<td>ES-08</td>
<td>ES-09</td>
<td>ES-10</td>
<td>ES-11</td>
<td>ES-12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Non-pharmacologic treatment of ADHD in children and...</td>
<td>Therapy of comorbid disorders in adult ADHD</td>
<td>How can I easily get update information on ADHD...?</td>
<td>Non-pharmacologic treatment of ADHD in adults</td>
<td>ADHD professional care in different cultural realities</td>
<td>Internet addiction and severe multiple media addiction...</td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>ES-07</td>
<td>ES-08</td>
<td>ES-09</td>
<td>ES-10</td>
<td>ES-11</td>
<td>ES-12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Update on the treatment of ADHD across the lifespan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>PL-04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Update on the treatment of ADHD across the lifespan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>PL-05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reward and motivation in ADHD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CME Accreditation

The 4th World Congress on ADHD is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS).

The 4th World Congress on ADHD is designated for a maximum of (or ‘for up to’) 18 hours of European external CME credits. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMAcredit can be found at www.ama-assn.org/go/internationalcme. Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

European physicians will be ascribed CME credits by the EACCME for the attendance at scientific sessions from Thursday, 6 June to Sunday, 9 June 2013. Full congress days count for 6 credits, half congress days for 3 credits. Please hand in the evaluation form enclosed in your congress bag to receive a printed copy of the accreditation certificate.
### General Assembly World Federation of ADHD

**14:00 – 15:00**

**Yellow 2**

General Assembly (for members only)

### HT-01  Hot Topic Symposium

**15:00 – 16:30**

**Yellow 3**

Research consortia present new findings
Chairpersons: K.-P. Lesch, Germany  
B. Franke, The Netherlands

**HT-01-001**  An overview of the genetics of adult ADHD—the IMPACT consortium  
A. Reif, Germany

**HT-01-002**  Overlap and differences between ADHD and ASD: Analyses of data from Neuroimage and BOA  
N. Lambregts-Rommelse, The Netherlands

**HT-01-003**  Abnormal reward anticipation in ADHD: A subtyping strategy  
J. Buitelaar, The Netherlands  
D. von Rhein, R. Cools

**HT-01-004**  Large-scale multicentre genetic studies in ADHD  
B. Franke, The Netherlands

### HT-02  Hot Topic Symposium

**15:00 – 16:30**

**Blue 1**

Symposium on the results of the international ADHD in substance use disorders prevalence (IASP) study: The first collaborative project of the ICASA foundation
Chairpersons: G. van de Giind, The Netherlands  
J. A. Ramos-Quiroga, Spain

**HT-02-001**  ADHD and substance abuse: A general perspective  
G. van de Giind, The Netherlands

**HT-02-002**  The prevalence of ADHD in treatment seeking SUD patients  
M. Konstenius, Sweden  
G. van de Giind, W. van den Brink

**HT-02-003**  Screening and diagnosis of ADHD in SUD patients  
J. A. Ramos-Quiroga, Spain

**HT-02-004**  Comorbidity and trauma in SUD patients with and without ADHD  
L. Meijvis, The Netherlands

### V5-01  Video Sessions

**15:00 – 16:30**

**Red**

Neuro-psychiatric movement disorders in children, adolescents and adults
Chairpersons: A. Warnke, Germany  
J. Volkmann, Germany  
E. C. Wolters, The Netherlands

### HT-03  Hot Topic Symposium

**17:00 – 18:30**

**Red**

Effects and mechanisms of psychotherapy in the treatment of ADHD in children and adults
Chairpersons: A. Philipsen, Germany  
T. Renner, Germany

**HT-03-001**  Results of a randomized controlled multicentre trial on the multimodal treatment of mothers and children both affected by ADHD (AIMAC)  
T. Jans, Germany

**HT-03-002**  Results of the randomised controlled multicentre trial on the multimodal treatment of adult ADHD (COMPAS)  
A. Philipsen, Germany

**HT-03-003**  Genes and psychotherapy in adult ADHD  
T. Renner, Germany

**HT-03-004**  Differential effects of psychotherapy and pharmacotherapy with methylphenidate on cerebral structure and neurochemistry in adults with ADHD  
L. Tebartz van Elst, Germany
<table>
<thead>
<tr>
<th><strong>HT-04</strong></th>
<th><strong>Hot Topic Symposium</strong></th>
<th><strong>YS-62</strong></th>
<th><strong>Young Scientist Sessions</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>17:00 – 18:30</strong></td>
<td>Yellow 3</td>
<td><strong>17:00 – 18:30</strong></td>
<td>Yellow 2</td>
</tr>
<tr>
<td><strong>Research on ADHD in Asia and Australia</strong></td>
<td><strong>Young Scientist Award Session</strong></td>
<td><strong>YS-62-001</strong> Extremely preterm children + mild neurodevelopmental disability + ADHD-symptoms = true?</td>
<td></td>
</tr>
<tr>
<td>Chairpersons: D. Silva, Australia S. Walitza, Switzerland</td>
<td>Chairpersons: L. A. Rohde, Brazil K. W. Lange, Germany</td>
<td>S. Elgen, Norway K. Sommerfelt, T. Markestad</td>
<td></td>
</tr>
<tr>
<td><strong>HT-04-001</strong> The concept of consilience in ADHD research in Korea: A developmental approach</td>
<td><strong>YS-62-002</strong> Why an apparent distraction would help ADHD children?</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HT-04-002</strong> Recent ADHD research in Japan</td>
<td><strong>YS-62-003</strong> Global and regional grey matter volumes in treatment-naïve vs. chronically treated children with Attention Deficit Hyperactivity Disorder: A voxel-based morphometry study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T. Saito, Japan</td>
<td>S. De Brito, United Kingdom H. Slama, A. Mary, D. Baleriaux, M. Kavec, T. Metens, P. Peigneux, I. Massat, T. Villemonteix</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HT-04-003</strong> Developing causal pathways and treatment outcomes for ADHD using multiple data sources: Western Australia population linkage study</td>
<td><strong>YS-62-004</strong> Predictive classification of adolescents with Attention Deficit Hyperactivity Disorder using structural magnetic resonance imaging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D. Silva, Australia L. Colvin, C. Bower</td>
<td>L. Lim, United Kingdom A. Cubillo, A. Smith, K. Chantiluke, A. Simmons, M. Mehta, A. Marquand, K. Rubia</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HT-04-004</strong> ADHD research in China</td>
<td><strong>Opening Ceremony</strong></td>
<td><strong>19:00 – 20:30</strong></td>
<td>Silver</td>
</tr>
<tr>
<td>Y. Wang, China</td>
<td><strong>Welcome Address and Opening Lecture</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HT-05</strong></td>
<td><strong>Hot Topic Symposium</strong></td>
<td></td>
<td><strong>YS-62-001</strong> Extremely preterm children + mild neurodevelopmental disability + ADHD-symptoms = true?</td>
</tr>
<tr>
<td><strong>17:00 – 18:30</strong></td>
<td>Blue 1</td>
<td><strong>YS-62-002</strong> Why an apparent distraction would help ADHD children?</td>
<td></td>
</tr>
<tr>
<td><strong>Risk pathways and ADHD prodomes</strong></td>
<td><strong>YS-62-003</strong> Global and regional grey matter volumes in treatment-naïve vs. chronically treated children with Attention Deficit Hyperactivity Disorder: A voxel-based morphometry study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chairpersons: J. Halperin, USA E. J. S. Sonuga-Barke, United Kingdom</td>
<td><strong>YS-62-004</strong> Predictive classification of adolescents with Attention Deficit Hyperactivity Disorder using structural magnetic resonance imaging</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HT-05-001</strong> “At risk” for ADHD: A developmental psychopathology perspective</td>
<td>L. Lim, United Kingdom A. Cubillo, A. Smith, K. Chantiluke, A. Simmons, M. Mehta, A. Marquand, K. Rubia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E. J. S. Sonuga-Barke, United Kingdom</td>
<td><strong>HT-05-002</strong> Who is at risk for ADHD?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G. Polanczyk, Brazil</td>
<td>S. De Brito, United Kingdom H. Slama, A. Mary, D. Baleriaux, M. Kavec, T. Metens, P. Peigneux, I. Massat, T. Villemonteix</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HT-05-003</strong> How genetics can inform the concept of at-risk in ADHD?</td>
<td><strong>HT-05-004</strong> Thinking about ADHD before the development of the full syndrome: The concept of at-risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. Franke, The Netherlands</td>
<td>J. Halperin, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HT-05-004</strong> Thinking about ADHD before the development of the full syndrome: The concept of at-risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J. Halperin, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ES-01  Educational Seminars
07:45 – 08:30  Red
Organisation and carrying out of parent training in ADHD and OCED
Chairperson: C. Neuhaus, Germany

ES-02  Educational Seminars
07:45 – 08:30  Yellow 3
How do differ ADHD from bipolar and conduct disorder?
Chairpersons: G. Polanczyk, Brazil
A. Reif, Germany

ES-03  Educational Seminars
07:45 – 08:30  Blue 1
How to do best medication in adult ADHD?
Chairpersons: P. Mattos, Brazil
S. Pallanti, Italy

ME-01  Meet the Experts
07:45 – 08:30  Yellow 1
Diagnosis of ADHD
Expert: L. A. Rohde, Brazil

ME-02  Meet the Experts
07:45 – 08:30  Yellow 2
ADHD over the lifetime
Expert: R. Klein, USA

ME-03  Meet the Experts
07:45 – 08:30  Blue 2
Pharmacological treatment of ADHD in children and adolescents
Expert: L. Greenhill, USA

PL-01  Plenary Sessions
08:30 – 10:30  Silver
Costs and benefits of ADHD
Chairpersons: L. A. Rohde, Brazil
A. Warnke, Germany

PL-01-001 Costs and benefits of ADHD
M. Schlander, Germany

PL-01-002 ADHD in academic and professional life
K. W. Lange, Germany

PL-01-003 Entrepreneurship and ADHD
M. Adamou, United Kingdom

PL-01-004 ADHD and driving
O. Tucha, The Netherlands

PL-02  Plenary Sessions
11:00 – 12:30  Silver
Approaches to the subtyping of ADHD
Chairpersons: A. Zuddas, Italy
S. Walitza, Switzerland

PL-02-001 Is there validity in subtyping ADHD
E. Willcut, USA

PL-02-002 ADD: An ADHD type or a different disorder?
R. A. Barkley, USA

PL-02-003 Families unhappy in their own right: Towards neurobiological subtyping of ADHD
K.-P. Lesch, Germany
M. Romanos, A. Reif, B. Franke

P-01  Guided Poster Tours
15:00 – 16:00  Poster Exhibition Hall B
Diagnosis I
Chairperson: M. Weiss, Canada

P-01-001 Differences between normal children with high and low scores on sluggish cognitive tempo: Preliminary data
E. Cardo Jalón, Spain
M. Servera, M. Bernad, G. Grasses, V. Meisel
P-01-002 Can developmental screening tools accurately identify children with ADHD in primary care?
M. Limbos, Canada
D. Joyce

P-01-003 A comparison of the ADHD symptoms between children and their both biological parents
J. Macek, Slovenia
M. Tomori

P-01-004 Development of an instrument to evaluate executive functions, delay aversion and state regulation for children with Attention Deficit Hyperactivity Disorder (ADHD)
B. Trevisan, Brazil
N. Andreoni, J. Prado, M. Muniz, D. Fernandes, A. Seabra

P-01-005 CBCL-derived psychopathological subtypes in children with ADHD
Y. Zenglein, Germany

P-01-006 FAST MINDS™: An educational programme for family care physicians to better recognize adult Attention Deficit Hyperactivity Disorder (ADHD) in primary care practice
T. Bilkey, Canada

P-01-007 The virtual classroom: An ecological tool for the assessment of the three dimensions of ADHD
S. Bioulac, France
S. Lallemand, J. Olive, A. Capelli, C. Fabrigoule, S. Rizzo, P. Philip, M. P. Bouvard

P-01-008 Paediatric ADHD and bipolar disorder: From common symptoms to differential diagnosis – can methylphenidate help to revise the diagnosis?
C. Chasqueira, Portugal
C. Viana, M. Alves, C. Nunes Filipe

P-01-009 LINK – the adult Attention Deficit Hyperactivity Disorder program (ADHD) connecting-educating-advancing
A. Fallu, Canada
L. Klassen

P-02 Guided Poster Tours
15:00 – 16:00 Poster Exhibition Hall B

Diagnosis II
Chairperson: J. Thome, Germany

P-02-001 Study in progress: Validation of the Swedish version of Weiss Functional Impairment Rating Scale, self rating (WFIRS-S); the importance of functional impairment in the diagnostic process
P. Jacobsson, Sweden

P-02-003 Reliability, validity and standardization of the Japanese version of the Conners’ Adult ADHD Rating Scales (CAARS)
M. Ohnishi, Japan

P-02-004 A study on screening tools for Attention Deficit Hyperactivity Disorder (ADHD) in Korea
T. W. Park, Republic of Korea
J.-C. Yang, Y.-C. Chung, S.-K. Chung, Y.-E. Jung, M. Lee

P-02-005 Diagnostic threshold prediction by gender according to the ASRS v1.1 in two samples of Mexican adults
E. Reyes Zamorano, Mexico
L. Palacios Cruz, A. Arias Caballero

P-02-006 What is considered abnormal sustaining of attention? A survey among teachers and parents of elementary school children
Y. Segal, Israel
T. Shani-Sherman, M. Levav, D. Gothelf

P-02-007 Detecting Attention Deficit Hyperactivity Disorder (ADHD): Examining predictive factors
T. Sernat, Canada
M. Mohamed, L. Anand, C. D’Ambrosio, I. Epstein, I. Szpindel, C. Cameron, M. Vermani, M. Katzman
**P-02-008** Delay in diagnosis of Attention Deficit Hyperactivity Disorder influenced by psychiatric comorbidities and parental educational level  
T. Vanicek, Austria  
C. Klier, C. Zenz, M. Maier, B. Hackenberg

**P-02-009** Categorical and dimensional assessment of ADHD in adults: The Barkley Adult ADHD Rating Scale IV (BAARS-IV) and the Adult ADHD Self Report Scale 1.1 (ASRS-1.1)  
B. Voinescu, Romania  
A. Szentagotai

---

**P-03** Guided Poster Tours  
15:00 – 16:00 Poster Exhibition Hall B

**Co-morbidity: Children and adolescents I**  
Chairperson: S. Waltzta, Switzerland

**P-03-001** The association between parenting stress, children mental health and environmental pollution exposure  
B. Balseviciene, Lithuania  
L. Sinkariova, S. Andrusaityte

**P-03-002** Relations with bipolar disorders, ADHD and ASD in childhood and adolescence  
K. Denda, Japan  
H. Ohmiya, T. Inoue, M. Miyajima

**P-03-003** Language impairment in children with Attention Deficit Hyperactivity Disorder  
F. Durão, Portugal  
M. J. Ximenes, C. Figueiredo, F. Abreu, S. Martins, M. Baptista

**P-03-004** Comorbidity in children and adolescents with Attention Deficit Hyperactivity Disorder in a Tunisian clinical population  
A. Harbaoui, Tunisia  
F. Charfi, A. Zaineb, S. BenRjeb, S. Halayem, S. Othman, A. Bouden

---

**P-03-005** Cognitive function and symptom levels of ODD, ADHD and emotional problems in ADHD children with and without social impairment  
O. A. Hovda, Norway  
M.-B. Posserud, L. Sørensen, A. J. Lundervold, K. Plessen

**P-03-007** Comorbidity in children with Attention Deficit Hyperactivity Disorder  
A. Lakic, Serbia  
A. Kesic

**P-03-008** Attention Deficit Hyperactivity Disorder like behavioural problems and parenting stress in paediatric allergic rhinitis  
Y. S. Lee, Republic of Korea  
D. H. Han, S. H. Kim, J. H. You

**P-03-009** Evaluating co-morbidities in an Attention Deficit Hyperactivity Disorder (ADHD) sample: Can Quantitative Electroencephalogram (QEEG) measures discriminate?  
N. Rutterford, United Kingdom  
H. Wachnianin, G. Kewley, S. Andersen

**P-03-010** Examination of spatial working memory performance in children and adolescents with Attention Deficit Hyperactivity Disorder, combined type (ADHD-CT) and anxiety  
A. Vance, Australia
<table>
<thead>
<tr>
<th>P-04</th>
<th>Guided Poster Tours</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00–16:00</td>
<td>Poster Exhibition Hall B</td>
</tr>
<tr>
<td>Co-morbidity: Children and adolescents II</td>
<td></td>
</tr>
<tr>
<td>Chairperson: C. Kieling, Brazil</td>
<td></td>
</tr>
<tr>
<td>P-04-001</td>
<td>Behavioural sleep problems and internalising and externalising co-morbidities in children with Attention Deficit Hyperactivity Disorder</td>
</tr>
<tr>
<td>K. Lycett, Australia &amp; E. Sciberras, F. Mensah, H. Hiscock</td>
<td></td>
</tr>
<tr>
<td>P-04-003</td>
<td>The relationship between weight and risk-taking behaviours in children with ADHD and other Disruptive Behaviour Disorders (DBDs)</td>
</tr>
<tr>
<td>M. Y. Ong, Singapore &amp; S.-J. Weng, D. S. Sheng Fung, M. J. Meaney</td>
<td></td>
</tr>
<tr>
<td>P-04-004</td>
<td>Long-term outcome in Tourette syndrome: The complexities of phenotype and treatment</td>
</tr>
<tr>
<td>R. Rizzo, Italy &amp; M. Gulisano, P. Call, P. Curatolo</td>
<td></td>
</tr>
<tr>
<td>P-04-005</td>
<td>Epileptiform abnormalities and epileptic seizure occurrence in children with ADHD and Tourette syndrome at baseline and at five years follow-up</td>
</tr>
<tr>
<td>D. Socanski, Norway &amp; A. Herigstad, S. Einarsdottir</td>
<td></td>
</tr>
<tr>
<td>P-04-006</td>
<td>Association of Attention Deficit Hyperkinetic Disorder and epilepsy: Further explored</td>
</tr>
<tr>
<td>P. Surathi, India &amp; S. G. T., C. Hongally</td>
<td></td>
</tr>
<tr>
<td>P-04-007</td>
<td>ADHD and co-morbidity report from India</td>
</tr>
<tr>
<td>A. Vaithiyam, India</td>
<td></td>
</tr>
<tr>
<td>P-04-008</td>
<td>Relations between callous-unemotional traits and behavioural symptoms in adolescent boys with ADHD</td>
</tr>
<tr>
<td>P. Garas, Hungary &amp; P. Vida, J. Halasz, J. Gadoros</td>
<td></td>
</tr>
<tr>
<td>P-04-009</td>
<td>Foster children and adolescents as inpatients: Risk factors and psychopathological specificities</td>
</tr>
<tr>
<td>C. Kayser, France &amp; M. Giannitelli</td>
<td></td>
</tr>
</tbody>
</table>

| P-04-010  | The correlation between comorbidity of ADHD and the aggression in adolescent with problematic online game play |
| D. H. Han, Republic of Korea & Y. S. Lee                                                       |

<table>
<thead>
<tr>
<th>P-05</th>
<th>Guided Poster Tours</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00–16:00</td>
<td>Poster Exhibition Hall B</td>
</tr>
<tr>
<td>Co-morbidity: Adults</td>
<td></td>
</tr>
<tr>
<td>Chairperson: A. Fossati, Italy</td>
<td></td>
</tr>
<tr>
<td>P-05-001</td>
<td>Anxiety and depression in caregivers of children with Attention Deficit Hyperactivity Disorder</td>
</tr>
<tr>
<td>I. Adeosun, Nigeria &amp; A. Adegbohun, O. Fatiregun, O. Ogun</td>
<td></td>
</tr>
<tr>
<td>P-05-002</td>
<td>Subjective sleep quality in a sample of patients presenting at an outpatient centre for adult Attention Deficit Hyperactivity Disorder</td>
</tr>
<tr>
<td>E. Ahlers, Germany &amp; H. Danker-Hopfe, M. Colla, D. Langner, L. Gentschow, C. Sauter</td>
<td></td>
</tr>
<tr>
<td>P-05-003</td>
<td>A follow-up study of Spanish young adults with ADHD: I. school functioning and risk behaviour</td>
</tr>
<tr>
<td>C. Colomer, Spain &amp; A. Miranda, R. Roselló</td>
<td></td>
</tr>
<tr>
<td>P-05-004</td>
<td>Personality disorders and executive function among adults with and without ADHD</td>
</tr>
<tr>
<td>P. Mayer Villa, Mexico &amp; L. Palacios Cruz, A. Arias Caballero, F. De la Peña Olvera, A. Vargas Soberanis, J. F. Cortes Sotres</td>
<td></td>
</tr>
<tr>
<td>P-05-005</td>
<td>Depression and anxiety in young male adults with ADHD</td>
</tr>
<tr>
<td>J. Ng, Singapore &amp; C. Cheok</td>
<td></td>
</tr>
<tr>
<td>P-05-006</td>
<td>Clinical and cognitive differences by gender and comorbidity in adult with ADHD symptoms</td>
</tr>
<tr>
<td>S. Ortiz, Mexico &amp; A. Jaimez, E. Reyes, G. Luna, F. De la Peña, C. Gaspar, A. Arias, O. Nafate, E. M. Cardenas, L. Palacios</td>
<td></td>
</tr>
</tbody>
</table>

26
P-05-007  Could comorbid bipolar disorder account for a significant share of executive function deficits in adults with ADHD?
K. Silva, Brazil

P-05-008  Affective temperamental traits in adults with Attention Deficit Hyperactivity Disorder and their relationship with psychopathological symptoms
F. Torrente, Argentina
P. Lopez, D. Alvarez Prado, M. Cetkovich-Bakmas, A. Lischinsky

P-20  Guided Poster Tours
15:00 – 16:00  Poster Exhibition Hall B
Pathophysiology: Children and adolescents II
Chairperson:  T. Renner, Germany

P-20-001  Analysis of emotional self-regulation using the child behaviour checklist (CBCL) and behaviour-rating inventory of executive function (BRIEF) in children with ADHD
M. Miranda, Brazil
S. Rizzutti, S. Palma, M. Muszkat, O. Bueno

P-20-002  Impaired oculomotor response inhibition in children with ADHD symptoms
A. Orylska, Poland
E. Racicka, T. Wolanczyk, E. Sypien, B. Balaj, G. Sedek

P-20-003  Assessment and reassessment four years later of the stress response in Brazilian children and adolescents with attention deficit disorder and hyperactivity: Do their symptoms persist?
S. M. Palma, Brazil
H. Calli, A. C. Natale

P-20-004  Is ADHD associated with risk seeking?
Y. Pollak, Israel
A. Oz, L. Kitrossky, V. Gross-Tsur

P-20-005  The role of emotional distress and ADHD in predicting institutional behavioural disturbance and recidivism among offenders
R. Gonzalez, United Kingdom
G. Gudjonsson, J. Wells, S. Young

P-20-006  Risky decision-making on gambling tasks in ADHD: A systematic literature review
Y. Groen, The Netherlands
G. F. Gaastra, O. Tucha

P-20-007  Everyday memory in children with Attention Deficit Hyperactivity Disorder
C.-C. Kao, Taiwan
P.-L. Tsai, I.-C. Chen

P-20-008  Do children with ADHD have poor motor function compared to normal control?
J.-H. Kim, Republic of Korea
S.-H. Shim

P-07  Guided Poster Tours
15:00 – 16:00  Poster Exhibition Hall B
Autism spectrum disorders I
Chairperson:  L. Tebartz van Elst, Germany

P-07-001  Social–communicative effects of the Picture Exchange Communication System (PECS) in autism spectrum disorders
A. Lema, Italy
D. Esposito, M. Conson, L. Russo, A. Massagli

P-07-003  On the role of the imbalance of macro-and micronutrients in the development of autism spectrum disorders
D. Tatiana, Belarus
M. Sergey, S. Natalia

P-07-004  Neurophysiological research of autism
D. Tatiana, Belarus
M. Sergey, M. Nikolai

P-07-005  Intra-subject variability in patients with Attention-Deficit/ Hyperactivity Disorder or autism spectrum disorders
K. Weissbrodt, Germany
N. Bednorz, C. W. N. Saville, C. Fleischhaker, R. Rauh, B. Feige, M. Biscaldi, C. Klein
**P-08 Guided Poster Tours**

**15:00 – 16:00**  
Poster Exhibition Hall B

**Epidemiology: Children and adolescents I**  
Chairperson: E. Willcut, USA

- **P-08-001**  
The Social Communication Questionnaire (SCQ) test – retest reliability in an epidemiological sample of national school children  
A. Boilson, Ireland  
S. Hourican, T. McVeigh, A. Staines, M. R. Sweeney

- **P-08-002**  
Gender differences in Egyptian adolescents with Attention Deficit Hyperactivity Disorder  
M. El Missiry, Egypt  
H. Rami, M. El Sheikh, A. El Missiry, Z. Bishry

- **P-08-003**  
The DSM-IV rates of childhood disorders in Turkey: Is ADHD a Turkish disorder?  
E. S. Erçan, Turkey  
Ö. Bilaç, T. Uysal, C. Aydin

- **P-08-004**  
Primary headaches, ADHD and learning difficulties in children and adolescents  
J. Genizi, Israel  
N. Kerem, I. Srugo, E. Shahar, S. Gordon, S. Ravid

- **P-08-005**  
Childhood ADHD in Micronesia  
A. Ghiasuddin, USA

- **P-08-006**  
Attention Deficit Hyperactivity Disorder in children and adolescents with traumatic dental injuries  
S. Hergüner, Turkey  
A. Hergüner, A. Erdur, F. A. Başçiftçi

- **P-08-007**  
The Attention Deficit Hyperactivity Disorder and family relationship  
V. L. Lima Ladeira Colonelli, Brazil

- **P-08-008**  
Psychosocial risk factors associated with Internet addiction in Korea  
Y. Shin, Republic of Korea  
J. Lee

**P-09 Guided Poster Tours**

**15:00 – 16:00**  
Poster Exhibition Hall B

**Epidemiology: Children and adolescents II**  
Chairperson: R. A. Barkley, USA

- **P-09-001**  
ADHD and the use of Internet  
C. Lara, Mexico  
A. X. Sánchez Millán

- **P-09-002**  
Qualitative sociological study on unmet needs (UN) among professionals involved in the detection and treatment of Attention Deficit Hyperactivity Disorder (ADHD): Spanish ADHD Action Plan (PANDAH)  
M. J. Mardomingo, Spain  

- **P-09-003**  
Motor coordination dysfunction in ADHD: Estimated prevalence of DAMP syndrome in Japan, using Japanese version of the Developmental Coordination Disorder Questionnaire (DCDQ)  
A. Nakai, Japan  
M. Ohnishi, Y. Mitsuhashi, B. N. Wilson

- **P-09-004**  
Distribution of ADHD in North West of England: Effect of socio-economic deprivation and access to community health services  
M. Ogundele, United Kingdom  
R. DeSoysa, I. Omenaka

- **P-09-005**  
Is socio-economic deprivation a common risk factor for the distribution of ADHD and ASD?  
M. Ogundele, United Kingdom  
R. DeSoysa

- **P-09-006**  
Behaviour disorders of children between 7 and 15 years old in Kayseri and the effecting factors  
V. Senol, Turkey  
D. B. Oztop, D. Unalan, D. Oztop, R. Peksen Akca, Y. Udül, S. S. Adanur, Ö. Metin, A. Günes, P. R. Cicek
P-09-007 Some characteristics of children diagnosed with ADHD and referred to the child protection centre of Zagreb
D. Štimac, Croatia
D. Kralj, G. Buljan Flander, D. Kralj, N. Škrlec, V. Križan

P-09-008 Prevalence of asthma in patients with Attention Deficit Hyperactivity Disorder: A nationwide population-based study
C.-J. Tsai, Taiwan
P.-H. Chou, C.-C. Lin, C.-H. Lin

P-09-009 Prevalence of Attention Deficit Hyperactivity Disorder and oppositional defiant disorder: A national survey in Thailand 2012
T. Visanuyothin, Thailand
P. Wachiradiolok, C. Pavasuthiapaisit, T. Booranasauskul

P-10-001 Circadian rhythm in adults with ADHD and the delayed sleep phase syndrome (DSPS): Melatonin profiles, activity and temperature
D. Bijlenga, The Netherlands

P-10-002 Using a national quality registry for monitoring ADHD treatment to study suicide attempts in young people and adults with ADHD
T. Edbom, Sweden
J.-O. Larsson

P-10-003 Attention Deficit Hyperactivity Disorder and violence: Findings from the adult psychiatric morbidity survey for England, 2007
R. Gonzalez, United Kingdom
C. Kallis, J. Coid

P-10-004 Factors related with the prevalence of ADHD in university students
Y. Kwak, Republic of Korea
M. Kim

P-10-005 A population-based examination of the prevalence of adult ADHD screening status and correlates in a Canadian samples
E. Vingilis, Canada
P. Erickson, R. Mann, M. Toplak, N. Kolla, U. Jain, J. Seely, M. van der Maas

P-11-001 Maternal recall, Second hand Smoke Exposure (SHS) and early childhood Attention Deficit Hyperactivity Disorder (ADHD) and disruptive disorders
M. Tandon, USA
C. N. Lessov-Schlaggar, R. Tillman, M. F. Hovell, J. Luby

P-11-002 ADHD with co-existing severe substance disorder (SUD) is characterized by early and persistent antisocial behaviour as well as poor general cognitive capacity
B. Bihlar Muld, Sweden
J. Jokinen, S. Bölte, T. Hirvikoski

P-11-003 Relationship between ADHD symptoms and alcohol use among patients with mood disorders
M. K. Janus, Canada
N. Lord, D. Almagor, R. Ansari

P-11-004 Adult Attention Deficit Hyperactivity Disorder: Associations between subtype and lifetime substance use – a clinical study
M. Liebrenz Rosenstock, Switzerland
A. Gamma, A. Frei, A. Buadze, E. Seifritz, D. Eich-Höchli

P-11-005 Adult Attention Deficit Hyperactivity Disorder and nicotine withdrawal: A qualitative study of patient perceptions
M. Liebrenz Rosenstock, Switzerland
A. Gamma, C. E. Fisher, A. Frei, A. Buadze, D. Eich-Höchli
P-11-006 Demographic profile of adults with Attention Deficit Hyperactivity Disorder (ADHD) with or without cocaine dependence
C. S. Miguel, Brazil
M. A. Gobbo, P. Martins, M. Klein, M. A. Silva, T. M. Alves, M. R. Louzã

P-11-007 Decision-making and impulsiveness in adults Attention Deficit Hyperactivity Disorder (ADHD) with and without cocaine dependence
C. S. Miguel, Brazil
M. A. Gobbo, P. Martins, M. Klein, M. A. Silva, T. M. Alves, M. R. Louzã

P-11-008 Features of prevention addictive behavior in children with mental retardation in the North-West of Russia
A. Soloviev, Russia
G. Skripnichenko, I. Novikova

P-12 Guided Poster Tours
15:00 – 16:00 Poster Exhibition Hall B

Aetiology I
Chairperson: S. Cortese, Italy

P-12-001 Theory of mind deficits in adults with Attention Deficit Hyperactivity Disorder
B. Oncu, Turkey
H. O. Altintas

P-12-002 A factorial structure of ADHD, sensation seeking and type A behaviour
A. Burke, South Africa
T.-L. Austin

P-12-003 A study on the emotion understanding in children with ADHD
G. Bohatchuk de Araujo, Brazil

P-12-004 A comparison of million clinical multi-axial inventory profiles between non-clinical, schizophrenia, substance use disorder and ADHD groups
A. Burke, South Africa
A. Vorster

P-12-005 Nutritional assessment of children and adolescents with Attention Deficit Hyperactivity Disorder
C. Carvalhosa, Brazil
S. Rizzutti, M. Vitalle, M. Mauro, M. Miranda, O. Bueno

P-12-006 The influence of parental behaviour on hyperactive-impulsive traits in children: Inattention as a mediator factor
D. Costa, Brazil
A. Alvim-Soares, D. Miranda, P. Mattos, B. Diniz, M. Romano-Silva, L. Malloy-Diniz

P-12-007 Fatty acid status and cognitive/behavioural symptoms in children with Attention Deficit Hyperactivity Disorder (ADHD): Preliminary data from an Italian study
A. Crippa, Italy
S. Conte, M. Molteni, M. Nobile

P-12-008 The effect of iron deficiency on etiology of Attention Deficit Hyperactivity Disorder among adolescent patients
M. Dabkowska, Poland
J. Horwatt-Baniewicz, P. Andrzejewski, M. Dambek

P-12-009 Psychophysiological, cognitive and behavioural correlates of emotional dysregulation in children and adolescents with internalizing and externalizing symptomatology
D. Esposito, Italy
I. Fanizza, L. Russo, A. Massagli

P-12-010 When parents and children have ADHD symptomatology: A literature review
V. Gonzalez Cantarero, Spain
G. Rosales Viladrich, J. Fornés Vives

P-12-011 Correlation between child-environment interaction and Attention Deficit Hyperactivity Disorder
M. Hamza, Tunisia
Z. Abbes, A. Harbaoui, F. Charfi, S. Halayem, S. Othman, A. Bouden

P-12-012 Autoantibodies targeting neurotransmitter biosynthetic enzymes in an ADHD sample
T.-A. Hegvik, Norway
E. S. Husebye, J. Haavik
The comparison of serum lead levels in children with ADHD and control group
M. Firouzkouhi Moghaddam, Iran
A. H. Heidary Poor

Association between poor sleep and early symptoms of Attention Deficit Hyperactivity Disorder
N. Stokbaek, Denmark

Actually really irresistible: Impulsivity predicts M&M (Smarties/cookies) consumption
A. Wirth, Germany

Mean platelet volume in children with Attention Deficit Hyperactivity Disorder
C. Mutlu, Turkey
O. Yorbik, I. A. Tanju, D. Celik, O. Ozcan

Attachment styles and Attention Deficit Hyperactivity Disorder (ADHD) symptoms in parents of the children and adolescents with ADHD
Y. Yulaf, Turkey
F. Ozer Gumustas, O. Sabuncuoglu

Meta-analysis of deficiencies in three domains of decision-making in adult ADHD
S. Ziegler, Norway
A. M. Mowinckel, E. Eilertsen, M. Zak, K. Høst, N. Eftedal

The role of omega-3 polyunsaturated fatty acids in clinical manifestation in children with Attention Deficit Hyperactivity Disorder
Y.-T. Huang, Taiwan
L. Jingling, J. -P.-Chen Chang, Y.-J. Liu, M. Palani, K.-P. Su
P-14 Guided Poster Tours
15:00 – 16:00 Poster Exhibition Hall B

Genetics I
Chairperson: B. Franke, The Netherlands

P-14-001 The stability of deficient emotional self-regulation symptoms in adolescence: The role of Tryptophan Hydroxylase 2 (TPH2) and of family structure
V. Bianchi, Italy
M. Bellina, A. Greco, D. Monzani, A. Tesei, M. Molteni, M. Nobile

P-14-002 Association study of latrophilin 3 gene with Attention Deficit Hyperactivity Disorder in Brazilian children and adolescents
E. Bruxel, Brazil

P-14-003 Interactions of MAOA, SYP and family environment in Attention Deficit Hyperactivity Disorder comorbid with oppositional defiant disorder in Chinese Han boys
G. Qian, People’s Republic of China
L. Liu, Y. Wang, Q. Qian, Y. Chen

P-14-004 Acetylcholine-metabolizing butyrylcholinesterase (BCHE) copy number and polymorphisms and their role in adult Attention Deficit Hyperactivity Disorder
J. Heupel, Germany
C. Jacob, H. Weber, S. Kittel-Schneider, K.-P. Lesch, A. Reif

P-14-005 Association of norepinephrine transporter genotype (NET1) with externalizing behaviour problems: Findings from a longitudinal study from birth to 15 years of age
E. Hohm, Germany

P-15 Guided Poster Tours
15:00 – 16:00 Poster Exhibition Hall B

Genetics II
Chairperson: K.-P. Lesch, Germany

P-15-001 Association of dopaminergic gene variants with traits of ADHD: A study on Indian probands
S. Maitra, India

P-14-006 A gene × gene interaction between COMT and DBH is associated with auditory attention deficit in boys with ADHD
J. Kang, Republic of Korea

P-14-007 The monoamine oxidase A gene promoter polymorphism, stressful life events, and impulsivity: Gene-environment interaction
E. Kiive, Estonia
K. Laas, M. Vaht, E. Comasco, L. Oreland, T. Veidebaum, J. Harro

P-14-008 Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in Attention Deficit Hyperactivity Disorder
B.-N. Kim, Republic of Korea
M. Bellgrove, S. C. Cho

P-14-009 Working memory and plasma brain-derived neurotrophic factor (BDNF) correlate with BDNF val66met in children with Attention Deficit Hyperactivity Disorder (ADHD) in Chinese Han subjects
H. Li, People’s Republic of China
L. Liu, Q. Qian, Y. Wang

P-14-007 The monoamine oxidase A gene promoter polymorphism, stressful life events, and impulsivity: Gene-environment interaction
E. Kiive, Estonia
K. Laas, M. Vaht, E. Comasco, L. Oreland, T. Veidebaum, J. Harro

P-14-008 Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in Attention Deficit Hyperactivity Disorder
B.-N. Kim, Republic of Korea
M. Bellgrove, S. C. Cho

P-14-009 Working memory and plasma brain-derived neurotrophic factor (BDNF) correlate with BDNF val66met in children with Attention Deficit Hyperactivity Disorder (ADHD) in Chinese Han subjects
H. Li, People’s Republic of China
L. Liu, Q. Qian, Y. Wang

I. Martensenkovsky, Ukraine
D. Martensenkovskyi
P-15-003 Association of monoamine oxidase A gene variants with behavioural co-morbidities: Scenario in Indian ADHD probands
K. Mukhopadhyay, India

P-15-004 Genetic variation in nicotinic acetylcholine receptors genes is associated with tobacco smoking susceptibility in patients with ADHD
E. R. Polina, Brazil

P-15-005 Contribution of folate system genes in Attention Deficit Hyperactivity Disorder
T. Saha, India
K. Mukhopadhyay, S. Dutta, P. Ghosh, S. Sinha

P-15-006 Association study of CDH13 and CTNNA2 genes with Attention Deficit Hyperactivity Disorder in Brazilian children and adolescents
A. Salatino de Oliveira, Brazil

P-15-007 Single trial P3b parameters are associated with COMT rs4680 genotype
C. Saville, Germany
C. Klein, T. Lancaster, B. Stephan, B. Stephan, U. Ettinger, B. Feige, M. Biscaldi, D. Linden

P-15-008 Clinical and cognitive differences in ADHD probands and adolescent siblings
L. Palacios Cruz, Mexico

P-15-009 Is ADHD restrictive subtype, which is specified by DSM-V a valid diagnosis? Holistic assessment with executive functions, genetic and multimodal brain imaging methods
S. Suren, Turkey
K. U. Yazici, A. Bacanli, C. Çalli, D. Aygunes, B. Kosava, C. Aydin, E. S. Ercan

P-16-001 Event related potentials in methylphenidate responder children with Attention Deficit Hyperactivity Disorder
H. Azzam, Egypt
A. Abd el Samee, A. Eissa, A. Amin, E. Abo el Ella

P-16-002 Different age effects on theta/beta ratio according to Attention Deficit Hyperactivity Disorder subtype
I. Buyck, Belgium
R. Wiersema

P-16-003 Testing between competing models of reinforcement deficit in ADHD using the electrophysiological-Monetary Incentive Delay (e-MID) task: Deficient motivation versus hyposensitivity to incentives
G. Chronaki, United Kingdom
N. Benikos, E. Sonuga-Barke

P-16-004 Normalization of ADHD symptoms by motivation-induced increase of arousal levels in children with ADHD
A. Conzelmann, Germany

P-16-005 The effect of methylphenidate on very low frequency electroencephalography oscillations in adult ADHD
C. Skirrow, United Kingdom
C. Tye, G. McLoughlin, J. Kuntsi, F. Rijsdijk, T. Banaschewski, D. Brandeis, P. Asherson, R. Cooper

P-16-006 The dysregulation of cortical activity in adult ADHD (aADHD): EEG aberrances of resting and cognitive activation states
A. Edge, South Africa
P-16-007 ADHD and first-episode schizophrenia display similar patterns of cortical hyper excitability—but they are distinctive
A. Hasan, Germany
M. Schneider, T. Schneider-Axmann, D. Ruge, W. Retz, M. Rössler, P. Falkai, T. Wobrock

P-16-008 EEG anomalies in adult ADHD subjects performing a working memory tasks
R. Hasler, Switzerland

P-16-009 The loudness dependence of the auditory evoked potential (LDAEP) and symptom severity in children with Attention Deficit Hyperactivity Disorder
E. J. Park, Republic of Korea
B. Kim, J. W. Kang, Y. H. Yang

P-16-010 Single trial P3b correlates of working memory impairments in Attention Deficit Hyperactivity Disorder (ADHD)
C. Saville, Germany
C. Klein, F. Bernd, M. Biscaldi, C. Fleischhaker, S. Bender

P-16-011 Modification of a recreational EEG technology for clinical application to ADHD and related disorders
I. Szpindel, Canada

P-16-012 EEG dynamics during initiation, realization and termination of movement in adolescents and adults with ADHD
A. Trembach, Russia
V. Tolokonikova, D. Samarskiy, T. Ponomareva

P-17 Guided Poster Tours

15:00 – 16:00 Poster Exhibition Hall B

Imaging studies I
Chairperson: K. Rubia, United Kingdom

P-17-001 The Default Mode Network (DMN) in paediatric patients with ADHD
E. Barragan, Mexico
S. Hidalgo, P. Dies, M. Obregon, P. Obregon, B. De Celis

P-17-002 Diffusion tensor imaging of the cerebellum-prefrontal area in ADHD paediatric patients
E. Barragan, Mexico
P. Dies, M. Obregon, P. Ibañez, H. de la Rosa, S. Hidalgo

P-17-003 Magnetic resonance spectroscopy in males with antisocial personality disorder: Effect of adult Attention Deficit Hyperactivity Disorder
C. Basoglu, Turkey

P-17-004 Regional gray matter volumetric differences between adolescents with ADHD versus controls plus its correlation to attention-related test scores
B. Bonath, Germany

P-17-005 The role of the cerebellum in Attention Deficit Hyperactivity Disorder: Structural and functional neuroimaging in ADHD
M. Dabkowska, Poland

P-17-007 Hemodynamic response of children with ADHD to happy and angry facial expressions
H. Ichikawa, Japan

P-17-008 Prefrontal dysfunction in adults with ADHD investigated with multi-channel near-infrared spectroscopy
A. Iwanami, Japan
Y. Okajima, C. Kanai, B. Yamagata, T. Izuno, A. Ikeda

P-17-009 Disorder-specific grey matter deficits in Attention Deficit Hyperactivity Disorder relative to autism spectrum disorder
L. Lim, United Kingdom
K. Chantiluke, A. Cubillo, A. Smith, A. Simmon, M. Mehta, K. Rubia
**P-18**  Guided Poster Tours
15:00 – 16:00  Poster Exhibition Hall B

**Imaging studies II**  
Chairperson: P. Shaw, USA

**P-18-001**  Abnormal frontal white matter diffusivity in preschool children with ADHD  
M. Mahone, USA  
D. Peterson, D. Crocetti, K. Slifer, M. Denckla, S. Mostofsky

**P-18-002**  Modulation by methylphenidate of neurofunctional networks involved in working memory in children with ADHD  
M. Septier, France  
T. Villemonteix, H. Slama, A. Mary, D. Baleriaux, T. Metens, P. Peigneux, I. Massat

**P-18-003**  Neuroimaging and neuropsychological analyses in a sample of children with ADHD: Inattentive subtype  
C. Mello, Brazil  
M. Muszkat, A. Jackowski, A. Rossi, L. Moura, T. Rivero, O. Bueno, T. Gusmão

**P-18-004**  Altered white matter microstructure in children with the inattentive subtype of Attention Deficit Hyperactivity Disorder  
J. Moya, Spain  
L. Gil-Martínez, M. García-Giral, R. Nicolau-Palou, A. Calvo-Boixet, K. Rubia

**P-18-005**  Adult ADHD a disease of failed neural timing?  
L. Schmueser, Germany  
A. Sebastian, K. Lieb, B. Feige, O. Tiescher

**P-18-006**  The default mode network response to rest cues and state-transitions in adults with Attention Deficit Hyperactivity Disorder  
J. Sidlauskaitė, Belgium  
J. R. Wiersema, E. Vassena, H. Roeyers, E. Sonuga-Barke

**P-18-007**  Working memory-related cerebral activity differences between good and bad performers in drug-naïve children with ADHD  
H. Slama, Belgium  
I. Massat, A. Mary, M. Kavec, S. Linotte, D. Balériaux, T. Metens, P. Peigneux

**P-18-008**  Representation of stimulus novelty in children and adolescents with ADHD  
J. Tegelbeckers, Germany  
N. Bunzeck, B. Bonath, H.-H. Flechtner, K. Krauel

**P-19**  Guided Poster Tours
15:00 – 16:00  Poster Exhibition Hall B

**Pathophysiology: Children and adolescents I**  
Chairperson: M. Romanos, Germany

**P-19-001**  Cognitive and neuropsychological assessment in a Portuguese sample of children with Attention Deficit Hyperactivity Disorder (ADHD)  
C. Alfaiate, Portugal  
J. Boavida, S. Nogueira, E. Fernandes, M. R. Simões

**P-19-002**  The influence of auditory novelty on the attentional performance in children with ADHD  
A. Lederer, Germany  
J. Tegelbeckers, L. Schares, B. Bonath, H.-H. Flechtner, K. Krauel

**P-19-003**  Executive function deficits: Distinguishing sluggish cognitive tempo from ADHD predominantly inattentive type  
E. Araujo, Mexico  
M. C. Jané, A. Bonillo

**P-19-004**  Association of ADHD symptoms and emotion regulation in a non-clinical sample  
R. Baur, Germany  
A. Conzelmann, M. Wieser, P. Paul

**P-19-005**  Sluggish cognitive tempo: Prevalence and clinical characteristics in a Spanish paediatric general population  
E. Camprodon, Spain  
M. Aceña, L. Duñó, S. Batlle, X. Estrada, N. Ribas, M. Marron, L. M. Martin

**P-19-006**  ADHD-related symptoms and the perception of emotion regulation difficulties in children  
C. Guluvica, Italy  
A. Grilli, N. Mitrofan, A. Rizzuto, M. Pesce
P-19-007  An integrated model of executive functioning is helpful to understand Attention Deficit Hyperactivity Disorder (ADHD) and associated disorders
A. Crippa, Italy

P-19-008  Verbal fluency in boys with ADHD
M. Dabkowska, Poland
M. Wilkosc, W. Chytra-Gedek, M. Mitros, J. Nowak

P-19-009  Information processing and perception abilities of children with Attention-Deficit/ Hyperactivity Disorder
R. Figaro, Brazil
F. Dias, M. Miranda, M. Muszkat, S. Rizzutti, O. Amodeo Bueno

HT-06  Hot Topic Symposium
16:30 – 18:00  Red

Is psychostimulant treatment of ADHD harmful for the patient?
Chairpersons: M. Gerlach, Germany
L. Greenhill, USA

HT-06-001 The pharmacology of medically used psychostimulants
M. Gerlach, Germany

HT-06-002 Adverse events of medication in association with ADHD and co-morbid mental disorders in a nationwide Danish sample over sixteen years
H.-C. Steinhausen, Denmark

HT-06-003 Is the treatment of ADHD with psychostimulants harmful for the dopaminergic system?
K. W. Lange, Germany

HT-06-004 Sudden death and use of stimulant medication in youths
L. Greenhill, USA

HT-07  Hot Topic Symposium
16:30 – 18:00  Yellow 1

ADHD – The subjective burden of disease
Chairpersons: O. Tucha, The Netherlands
I. Manor, Israel

HT-07-001 Quality of life in ADHD
M. Danckaerts, Belgium

HT-07-002 Stigmatization in ADHD
A. B. M. Fuemaier, The Netherlands

HT-07-003 Self-esteem, self-efficacy and resources in adults with ADHD
R.-D. Stieglitz, Switzerland

HT-07-004 Self-awareness/complaints of patients with ADHD
I. Manor, Israel

HT-08  Hot Topic Symposium
16:30 – 18:00  Yellow 3

The role of sleep problems and circadian clock genes in ADHD
Chairpersons: J. Thome, Germany
A. Coogan, Ireland

HT-08-001 Circadian rhythms in ADHD: The role of clock genes
A. Coogan, Ireland

HT-08-002 What is chronotherapy?
J. Thome, Germany

HT-08-003 Sleep disturbance, circadian preference and symptoms of adult ADHD
L. Mateescu, Romania

HT-08-004 Circadian rhythm problems and delayed sleep phase in ADHD: From research to clinical practice
L. Imeraj, Belgium
I. Antrop, D. Deboutte, H. Roeyes, E. Sonuga-Barke
### HT-09 Hot Topic Symposium

**16:30 – 18:00 Blue 1**

**Personality disorder in adult ADHD**
Chairpersons: J. A. Ramos-Quiroga, Spain
F. Reimherr, USA

**HT-09-001** Personality profile of adult ADHD: The alternative five-factor model  
J. A. Ramos-Quiroga, Spain

**HT-09-002** Childhood ADHD and borderline personality disorder: Developmental issues and controversial aspects  
A. Fossati, Italy

**HT-09-003** Are temperament profiles different in early and late onset adult ADHD  
C. B. Surman, USA

**HT-09-004** Genetics correlations and personality in adults with ADHD  
A. Merwood, United Kingdom

### HT-10 Hot Topic Symposium

**16:30 – 18:00 Blue 2**

**Vigilance regulation model of ADHD and affective disorders**
Chairpersons: U. Hegerl, Germany
M. Romanos, Germany

**HT-10-001** Dysregulation of vigilance as a pathogenetic factor in affective disorders and ADHD  
U. Hegerl, Germany

**HT-10-002** Vigilance regulation in ADHD  
M. Romanos, Germany

**HT-10-003** Geographic variation in the prevalence of ADHD: Circadian and sleep aspects of ADHD  
M. Arns, The Netherlands
K. van der Heijden, L. E. Arnold, J. L. Kenemans

**HT-10-004** The sleep phenotypes and therapeutic options for ADHD  
S. Miano, Italy

### YS-63 Young Scientist Sessions

**16:30 – 18:00 Yellow 2**

**Young Scientist Award Session**
Chairpersons: F. X. Castellanos, USA
T. Renner, Germany

**YS-63-001** Methylphenidate-regulated genes in lymphoblastoid cell lines of adult ADHD patients  
S. Kittel-Schneider, Germany
R. Schwarz, S. Reichert, C. Jacob, A. Reif

**YS-63-002** Expression study on the ADHD candidate latrophilin 3 in mononuclear blood cells  
J. Fuchs, Germany

**YS-63-003** Association between GUC2C and Attention Deficit Hyperactivity Disorder in Chinese Han subjects: Evidence from both categorical and quantitative traits  
L. Liu, People’s Republic of China
Y. Wang, H. Li, L. Yang, Q. Qian

**YS-63-004** Diffusion tensor imaging in a Brazilian sample of Attention Deficit Hyperactivity Disorder children: Preliminary data evidence reduced fractional anisotropy in tracts connecting anterior and posterior attentional systems  
G. Pastura, Brazil
P. Mattos, E. L. Gasparetto, A. P.Q.C. Araújo

### Please visit the Technical Exhibition

**Opening hours**

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday</td>
<td>6 June 2013</td>
<td>15:00 – 21:00</td>
</tr>
<tr>
<td>Friday</td>
<td>7 June 2013</td>
<td>09:00 – 18:00</td>
</tr>
<tr>
<td>Saturday</td>
<td>8 June 2013</td>
<td>09:00 – 18:00</td>
</tr>
<tr>
<td>Sunday</td>
<td>9 June 2013</td>
<td>09:00 – 13:00</td>
</tr>
</tbody>
</table>
ES-04  Educational Seminars

07:45 – 08:30  Yellow 2

How to do neurofeedback in ADHD?
Chairpersons: P. Siegel-Gradenwitz, United Kingdom
U. Strehl, Germany

ES-05  Educational Seminars

07:45 – 08:30  Yellow 3

Comorbid disorders or attention-deficit-spectrum disorders?
Chairpersons: C. Freitag, Germany
C. Kieling, Brazil

ES-06  Educational Seminars

07:45 – 08:30  Blue 1

Assessment of adult ADHD
Chairpersons: C. Jacob, Germany
F. Reimherr, USA

ME-04  Meet the Experts

07:45 – 08:30  Red

Predictors of persistent ADHD
Expert: J. Biedermann, USA

ME-05  Meet the Experts

07:45 – 08:30  Yellow 1

Neurobiology of ADHD
Expert: F. Castellanos, USA

ME-06  Meet the Experts

07:45 – 08:30  Blue 2

Treatment of adult ADHD
Expert: M. Weiss, Canada

Registration fee for Educational Seminars and Meet the Experts, per session: EUR 30.
Only valid in combination with the congress registration fee.
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-06-003</td>
<td>The Social Communication Questionnaire (SCQ) discriminant validity in an epidemiological sample of national school-children</td>
<td>A. Boilson, Ireland A. Staines, M. R. Sweeney</td>
</tr>
<tr>
<td>P-06-004</td>
<td>Development and Implementation of a European protocol for Autism Spectrum Disorder Prevalence (EPAP)</td>
<td>A. Boilson, Ireland A. Ramirez, M. Posada, A. Staines, M. R. Sweeney</td>
</tr>
<tr>
<td>P-06-005</td>
<td>The Social Communication Questionnaire (SCQ) Distribution of scores by gender in an epidemiological sample of national school children</td>
<td>A. Boilson, Ireland A. Staines, M. R. Sweeney</td>
</tr>
<tr>
<td>P-06-006</td>
<td>Implementation of a European protocol for autism spectrum disorder prevalence</td>
<td>A. Boilson, Ireland A. Staines, M. R. Sweeney</td>
</tr>
<tr>
<td>P-21-004</td>
<td>The moderating role of parental education in the relation between ADHD symptoms and executive functions</td>
<td>C. Tillman, Sweden V. Granvald</td>
</tr>
<tr>
<td>P-21-005</td>
<td>Executive function impairments in ADHD</td>
<td>S. Valagussa, Italy G. M. Marzocchi</td>
</tr>
<tr>
<td>P-21-006</td>
<td>Interference of emotional information on task performance in children and adolescents with Attention Deficit Hyperactivity Disorder</td>
<td>V. van Cauwenberge, Belgium J. R. Wiersema, K. Hoppenbrouwers, K. van Leeuwen</td>
</tr>
<tr>
<td>P-21-007</td>
<td>Assessment for attention – Neuropsychological values describing cognitive attentional functioning in ADHD</td>
<td>L. J. Weiler, Austria A. Schuch-Brendel, A. Mikula, U. Leiss</td>
</tr>
<tr>
<td>P-21-008</td>
<td>Comparison of attention function between children and adolescents with ADHD: Preliminary study</td>
<td>Y. Younghui, Republic of Korea E.-J. Park</td>
</tr>
<tr>
<td>P-21-009</td>
<td>Are choices between short and long-term rewards mediated by time perception in children with Attention Deficit Hyperactivity Disorder (ADHD): Delay aversion or state regulatory deficit?</td>
<td>X. Yu, People’s Republic of China X. Liu</td>
</tr>
<tr>
<td>P-21-010</td>
<td>Executive functions profile in children and adolescents with or without ADHD: By using performance-based measures and homework and work habits (HWH) questionnaire</td>
<td>Y. Yulaf, Turkey S. Gokçe Imren, F. Gumustas, Y. Yazgan</td>
</tr>
</tbody>
</table>
P-22

Guided Poster Tours

15:00 – 16:00 Poster Exhibition Hall B

Pathophysiology: Adults
Chairperson: R. Klein, USA

P-22-001 The effects of methylphenidate on decision making in an adult ADHD sample: A pilot study
M. L. Pedersen, Norway
A. M. Mowinckel, M. Fredriksen, G. P. Biele

P-22-002 Access to long-term memory is impaired in adult patients with Attention Deficit Hyperactivity Disorder
V. Bueno, Brazil
M. A. da Silva, T. M. Alves, M. R. Louzã, S. Pompéia

P-22-003 Complex prospective memory in adults with Attention Deficit Hyperactivity Disorder
A. B. M. Fuermaier, The Netherlands

P-22-004 Neuropsychological characteristics in adults with ADHD
I. Hach, Germany
U. Ruhl

P-22-005 A follow-up study of Spanish young adults with ADHD: II. Correlates with functional impairment
C. Colomer, Spain
A. Miranda, R. Roselló

P-22-006 The influence of methylphenidate medication on reinforcement learning in adults with ADHD
A. M. Mowinckel, Norway
M. Fredriksen, G. Biele

P-22-007 ADHD traits and distractibility
M. Panagiotidi, United Kingdom
T. Stafford, P. Overton

P-22-008 Neuropsychological deficits in adults with ADHD: Are they clinically relevant?
M.-F. Pelletier, Canada
S. Tremblay, A. Vincent, M. Lafleur

P-22-009 Cortisol awakening response (CAR) in adults with Attention Deficit Hyperactivity Disorder (ADHD): Differences by subtype and gender
J. A. Ramos-Quiroga, Spain
M. Corominas, G. Palomar, R. Bosch, V. Ribes, J. Paris, M. Nogueira, M. Corrales, M. Casas

P-22-010 ADHD is associated with slow finger movement
G. Todd, Australia
M. Leach, S. Hillier, E. Hotham, J. White

P-22-011 Assessment of executive functions in adults: Validation of the Spanish-language Barkley deficits in executive functioning scale (BDEFS)
M. Velez-Pastrana, Puerto Rico

P-22-012 Emotional dysregulation and the severity of the ADHD symptomatology in adults
S. Corbisiero, Switzerland
B. Mørstedt, J. Buchli-Kammermann, R.-D. Stieglitz

P-23

Guided Poster Tours

15:00 – 16:00 Poster Exhibition Hall B

Pharmacological treatment: Children and adolescents I
Chairperson: T. Banaschewski, Germany

P-23-001 Attention Deficit Hyperactivity Disorder treatment effects: A systematic review of long-term outcomes
L. E. Arnold, USA
P. Hodgkins, H. Caci, J. Kahle, S. Young

P-23-002 Post hoc comparison of the efficacy of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate in children and adolescents with Attention Deficit Hyperactivity Disorder
T. Banaschewski, Germany
M. Leendreux, C. Soutullo, M. Johnson, A. Zuddas, C. Anderson, R. Civil, N. Higgins, R. Bloomfield, L. Squires, D. Coghill
P-23-003  Therapy Combination: A prevalent pattern among children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) treated with stimulants in the Canadian province of Quebec
L. Benamor, Canada
V. Sikirica, G. De, J. Lachaine, J. van Stralen, J. Heroux, H. Yang, P. Hodgkins

P-23-005  Using family preference to determine the best medication (stimulant or non-stimulant) for treatment of a child with ADHD
R. Bergh, Canada

P-23-006  Atomoxetine in severe comorbid adolescents with antisocial behavior: Clinical in-patient data and review of the literature
O. Bilke-Hentsch, Switzerland

P-23-007  Effectiveness and safety of a long-acting methylphenidate formulation in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) under daily practice conditions
O. Bilke-Hentsch, Switzerland
F. Härtling, B. Mueller

P-23-008  Continuous Performance Test (CPT) as a useful instrument for everyday clinical practice
J. Boavida, Portugal
C. Alfaiate, M. Almeida, S. Nogueira, E. Fernandes, M. J. Seabra Santos

P-23-009  A head-to-head, double-blind, randomized, phase 3b trial comparing the efficacy of lisdexamfetamine dimesylate with atomoxetine on core symptoms in children and adolescents with Attention Deficit Hyperactivity Disorder
R. Dittmann, Germany
E. Cardo Jalón, D. Coghill, P. Nagy, B. Adeyi, C. Anderson, R. Bloomfield, B. Caballero, N. Higgins, P. Hodgkins, R. Civil

P-23-010  Historical trends in comorbid bipolar disorder and ADHD
R. Fieve, USA
J. Prosser, M. Gilbert

P-23-011  A head-to-head, double-blind, randomized, phase 3b trial comparing the efficacy and safety of lisdexamfetamine dimesylate with atomoxetine for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder
R. Dittmann, Germany
E. Cardo Jalón, D. Coghill, P. Nagy, C. Anderson, R. Bloomfield, B. Caballero, N. Higgins, P. Hodgkins, A. Lyne, R. Civil

P-24  Guided Poster Tours
15:00 – 16:00  Poster Exhibition Hall B
Pharmacological treatment: Children and adolescents II
Chairperson:  L. Greenhill, USA

P-24-001  Methylphenidate improves handwriting of children with ADHD; a systematic review of controlled clinical trials
A. Ghanizadeh, Iran
M. Ghanbari

P-24-002  Explaining ethnic differences in the use of stimulant medications for ADHD: A whole-population study
M. Ghosh, Australia
D. Holman, D. Preen

P-24-003  A caregiver perspective of symptom burden among children and adolescents with ADHD in the UK
V. Harpin, United Kingdom
E. Flood, K. Gajria, V. Sikirica, C. N. Dietrich, B. Romero, K. Beusterien, M. H. Erder

P-24-004  Resource utilization and costs of newly diagnosed ADHD-patients in Germany: A comparison of drug treatment-persistent, drug treatment-non-persistent, and nondrug-treated patients
P. Hodgkins, USA
S. Braun, J. Zeidler, R. Linder, L. Russo
P-24-005 Patient characteristics associated with treatment initiation among paediatric patients with Attention Deficit Hyperactivity Disorder (ADHD) symptoms in Central Europe and Eastern Asia
J. Hong, United Kingdom
D. Novick, T. Treuer, J. M. Haro, W. Montgomery, S. Wu, V. Haynes

P-24-006 Association between six week response and subsequent remission in the treatment of paediatric patients with Attention Deficit Hyperactivity Disorder (ADHD) symptoms in Central Europe and Eastern Asia
J. Hong, United Kingdom
D. Novick, T. Treuer, J. M. Haro, W. Montgomery, S. Wu, V. Haynes

P-24-007 Children medicated for ADHD exhibit impaired motor performance
E. Hotham, Australia
S. Hillier, M. Leach, J. White, G. Todd

P-24-008 Differences in the maintenance of stimulants: One year follow-up study
J.-W. Hwang, Republic of Korea
S.-J. Lee, B.-N. Kim, S.-C. Cho

P-24-009 OROS MPH in treatment of ADHD in children and adolescents with comorbid chronic motor tic disorder
A. Kesic, Serbia
A. Lakic, P. Ignjatovic

P-24-010 Therapeutic response of methylphenidate in ADHD core symptoms depending on dose: Low, medium and high
S. Batlle Vila, Spain

P-24-011 Is MPR (Medication Possession Ratio) critical for ADHD treatment?
M. Hong, Republic of Korea
G. H. Bahn, Y. J. Lee

P-24-12 Resource utilization and costs of treating newly diagnosed ADHD patients in Germany
Paul Hodgkins, USA
S. Braun, J. Zeidler, R. Linder, L. Russo

P-25 Guided Poster Tours

15:00 – 16:00 Poster Exhibition Hall B
Pharmacological treatment: Children and adolescents III
Chairperson: J. Biederman, USA

P-25-001 Influences of stimulant therapy on K-WISC-III in Korean boys with ADHD
J. S. Lee, Republic of Korea
S.-Y. Cho, S.-M. Ock

P-25-002 Parental perception of ADHD following treatment at a child psychiatric clinic in Singapore
C. G. Lim, Singapore

P-25-003 Atomoxetine and central nervous system stimulants treatment pattern in medicaid youths
S. Linden, USA
A. Winterstein

P-25-004 São Paulo (Brazil) public ADHD drug distribution programme: Review after five years of deployment
S. M. Palma, Brazil

P-25-005 Lisdexamfetamine dimesylate effect in central auditory processing of children with ADHD
E. Ayres, Botswana
M. Prando, A. L. Moraes, F. Mugnol

P-25-006 Revisiting the side effects of methylphenidate in children with Attention Deficit Hyperactivity Disorder (ADHD)
P. Robaey, Canada
S. Kuehn, J. Munroe, M. Lifshin, B. Décarie, D. Aggarwal, B. Jones, W. James, F. O’Kelly

P-25-007 Atomoxetine improves executive functions performance in children with Attention Deficit Hyperactivity Disorder
B. Rubio Morell, Spain
S. Hernández Expósito
P-25-008 Measuring functioning in adolescents with ADHD: Do existing tools reflect the adolescents’ perspective?
J. Setyawan, USA
A. Hareendran, M. H. Erder, P. Hodgkins, D. Trundell, R. Pokrzywinski

P-25-009 Treatment patterns among children and adolescents having Attention Deficit Hyperactivity Disorder (ADHD) with or without psychiatric or neurologic comorbidities in Sweden
V. Siskirica, USA
J. Yeaw, P. A. Gustafsson, T. G. Curtice, M. Rucker, P. Hodgkins, C. Makin

P-25-010 A dose adaptation approach of methylphenidate (MPH) for children with Attention Deficit Hyperactivity Disorder (ADHD)
G. Bonnefois, Canada
P. Robaey, O. Barrière, J. Li, F. Nekka

P-26 Guided Poster Tours

15:00 – 16:00 Poster Exhibition Hall B

Pharmacological treatment: Children and adolescents IV
Chairperson: A. Zuddas, Italy

P-26-001 Effects of methylphenidate treatment on antioxidative capacity and ROS formation in the blood of children with ADHD
O. Sommer, Germany
H.-W. Clement, M. Röttinger, P. Heiser, H.-W. Clement, E. Schulz

P-26-002 Psychostimulant enhances cognitive controls through STROOP test in children with ADHD
D. -H. Song, Republic of Korea
K. Jhung, S. Kook, K.-a. Cheon

P-26-003 Health and social costs of Attention Deficit Hyperactivity Disorder (ADHD) among patients who respond (RD) to drug therapy vs. non-responders (NRD) in Spain (preliminary results)
C. Soutullo, Spain

P-26-004 Atomoxetine-induced life-threatening long QT syndrome
M. Stuhec, Slovenia
V. Svab

P-26-005 A comparison of the long-term adherence patterns of OROS methylphenidate and atomoxetine in children with Attention Deficit Hyperactivity Disorder
Y. Su, People’s Republic of China
Y. Wang, L. Yang

P-26-006 Predictors of pharmacological treatment outcomes in patients with Attention Deficit Hyperactivity Disorder from Non-Western countries
T. Treuer, Hungary
Q. Feng, D. Desaijah, M. Altin, S. Wu, A. El-Shafei, E. Serebryakova, M. Gado, D. Faries

P-26-007 The effect of OROS-MPH and gonadotropin releasing hormone analogue in a male patient with ADHD and precocious puberty associated with hypothalamic hamartoma
Y. Yamashita, Japan
K. Katayma, S. Yatsuaga, Y. Koga, T. Matsuishi

P-26-008 The clinical profile of children with ADHD that require a OROS-methylphenidate combined with shorter acting formulations
N. Zelnik, Israel

P-26-009 Clinical efficacy of lisdexamfetamine dimesylate in children and adolescents with Attention Deficit Hyperactivity Disorder: A post hoc analysis
A. Zuddas, Italy
T. Banaschewski, M. Lecendreux, C. Soutullo, M. Johnson, C. Anderson, R. Civil, B. Adeyi, L. Squires, D. Coghill

P-26-010 Efficacy and safety extrapolation analyses for atomoxetine in young children with Attention Deficit Hyperactivity Disorder
H. Upadhyaya, USA
C. Kratochvil, J. Ghuman, A. Camporeale, S. Lipsius, D. DSouza, Y. Tanaka
P-27-001 Lisdexamfetamine Dimesylate (LD) in adult Attention Deficit Hyperactivity Disorder (ADHD)
F. Abuzzahab, USA
N. Prange, K. Abuzzahab

P-27-002 Response rates of adults with ADHD in multicentre placebo controlled trials of atomoxetine: An integrated analysis
P. Asherson, United Kingdom
C. Bushe, K. Saylor, Y. Tanaka, W. Deberdt, H. Upadhyaya

P-27-003 Efficacy of OROS-methylphenidate on specific EF deficits in adults with ADHD: A randomized, double blind, placebo-controlled crossover study
A. Bron, The Netherlands
D. Bijlenga, A. M. Boonstra, M. Breuk, W. Pardoen, A. T. F. Kooij

P-27-004 Cardiovascular and metabolic risks in adult ADHD patients before and after treatment with stimulants and non-stimulants: Preliminary findings
A. Gabriel, Canada

P-27-005 Methylphenidate Hydrochloride Modified Release (MPH–LA) in adults with Attention Deficit Hyperactivity Disorder (ADHD): Self-rated, observer-rated and physician-rated assessments show consistently significant improvement compared to placebo
Y. Ginsberg, Sweden

P-27-006 Health state utilities associated with adult ADHD
V. Haynes, USA

P-27-007 Course of pharmacological treatment of adult ADHD
K. Naidoo, United Kingdom
C. Willis, U. Ashraf

P-27-008 Lamotrigine for Attention Deficit Hyperactivity Disorder comorbid with mood disorders: Case series
B. Oncu, Turkey
O. Er, B. Colak

P-28-001 Investigating the best treatment for the Delayed Sleep Phase Syndrome in adults with Attention Deficit Hyperactivity Disorder and its effect on health and appetite
S. Vogel, The Netherlands
D. Bijlenga, S. Kooij

P-28-002 Methylphenidate treatment of adult long-term prison inmates with ADHD: A randomised double-blind placebo-controlled trial with open-label extension
Y. Ginsberg, Sweden
T. Hirvikoski, M. Grann, N. Lindefors

P-28-003 Severity but not comorbidities predicts response to methylphenidate in adults with ADHD: Results from a naturalistic study
M. Victor, Brazil
P-28-004 40-week, randomized, double-blind, placebo-controlled, multi-centre, efficacy and safety study of Methylphenidate Hydrochloride Modified Release (MPH–LA) in adults with Attention Deficit Hyperactivity Disorder (ADHD)
M. Huss, Germany

P-28-005 Mathematical modelling of CPT performance discriminates methylphenidate medication persisters from non-persisters in adult ADHD
S. Ziegler, Norway
M. Fredriksen, G. Biele

P-28-006 A 40-week, double-blind, placebo-controlled, efficacy and safety study of Methylphenidate Hydrochloride Modified Release (MPH–LA) in adult ADHD: Study design
V. Kumar, USA

P-28-007 Methylphenidate Hydrochloride Modified Release (MPH–LA) safety profile in adults with Attention Deficit Hyperactivity Disorder (ADHD): Results of a 40-week, randomized, double-blind, placebo-controlled, multi-centre, efficacy and safety study
V. Kumar, USA

P-28-008 Efficacy and safety of atomoxetine hydrochloride in a placebo-controlled randomized withdrawal study in adults with Attention Deficit Hyperactivity Disorder
H. Upadhyaya, USA
D. Williams, J. Lane, A. Camporeale, Y. Tanaka

P-28-009 A 40-week, randomized, double-blind, placebo-controlled, multicenter, efficacy and safety study of Methylphenidate Hydrochloride Modified Release (MPH–LA) in adult Attention Deficit Hyperactivity Disorder: Maintenance of treatment effect
M. Huss, Germany

P-29 Guided Poster Tours
15:00 – 16:00 Poster Exhibition Hall B
Pharmacogenetics
Chairperson: J. Buitelaar, The Netherlands

P-29-001 Adverse reactions to methylphenidate in twins – A report on three pairs
I. Aguiar, Portugal
M. Fonseca, P. Mendes, G. Fernandes, V. Martins

P-29-002 Altered response with methylphenidate to ADHD-like symptoms in pervasive developmental disorder: Does CES-1 enzyme gene polymorphism play a role?
E. S. Erkan, Turkey
U. Akyol Ardic, D. Yuce, E. Erkan, D. Aygunes, B. Kosova

P-29-003 Norepinephrine transporter gene polymorphism and side effect of OROS methylphenidate in Attention Deficit Hyperactivity Disorder
H. Kang, Republic of Korea
K.-H. Yook, J. Song, H. J. Hong

P-29-004 Role of gene-dose interaction between SLC6A2 polymorphism and methylphenidate to treatment outcome in Korean ADHD children
J. Kang, Republic of Korea
E. J. Park, J. Y. Lee, B. Kim

P-30 Guided Poster Tours
15:00 – 16:00 Poster Exhibition Hall B
Non pharmacological treatment I
Chairperson: T. Jans, Germany

P-30-001 Cognitive training in drug-naïve children with Attention Deficit/ Hyperactivity Disorder (ADHD)
A. Bikic, Denmark
J. Leckman, J. Lindschou Hansen, T. Østergaard Christensen, S. Dalsgaard

P-30-002 Different perception of attention and social problems between parents and teachers of children with ADHD
P. Brambilla, Italy
F. Fabbro
P-30-003  The effect of physical exercise on cognition and behaviour in children with ADHD: A systematic literature review
A. Den Heijer, The Netherlands
Y. Groen, L. Tucha, A. Fuermaier, J. Koerts, K. Lange, O. Tucha

P-30-004  Moving from efficacy to effectiveness research for psychosocial treatments for preschool ADHD: Challenges in the translation to different cultures
A.-M. Lange, Denmark
D. Daley, C. Laver-Bradbury, C. Rask, E. Sonuga-Barke, M. Thompson, P. H. Thomsen

P-30-005  A preliminary investigation of aggression in children with ADHD following a brain-computer interface intervention
X. Y. Lee, Singapore

P-30-006  Experience of autoregulation training and assisted therapy with dog for children with ADHD
L. Luccherino, Italy
M. V. Romizi, V. Andreini, S. Merli, P. Piras

P-30-007  Development of an intervention programme on executive functions for children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
B. Trevisan, Brazil
A. Menezes, A. Seabra

P-30-008  Dance movement therapy (DMT) and methylphenidate, combined treatment may be a better option for managing ADHD children
D. Pan, India
M. Sarkar, S. Chakraborty

P-30-009  Cognitive training effects in children with reading difficulties: A pilot study
N. Pereira, Portugal
A. Costa, M. Guerreiro

P-30-010  Can daily physical activity improve executive functions and school performances? A pilot study
L. Santinelli, Switzerland
P. Andreazzi

P-31-001  ADHD symptoms in pre-schoolers: A follow-up study on the effectiveness of a parent-training programme
A. Azevedo, Portugal
M. J. Seabra-Santos, M. F. Gaspar, T. Carvalho Homem, M. Pimentel, S. Leitão

P-31-002  Neurofeedback training in adolescent with ADHD: A single case study with thompson protocol
E. Barei, Italy
L. Lorenzon, A. Zanella

P-31-003  The token economy technique to forecast consequences for management to postpone the reward for ADHD
L. F. Coelho, Brazil
M. C. Miranda, D. L. Fernades Barbosa, M. Muszkat, S. Rizzutti, S. M. M Palma, O. F. Amodeo Bueno

P-31-005  Efficacy of a behavioural sleep intervention in children with ADHD: A randomised controlled trial
E. Sciberras, Australia
F. Oberklaid, F. Mensah, D. Efron, H. Hiscock

P-31-006  The effects of group social skill training for ADHD children with social skill deficit
M.-S. Shin, Republic of Korea
M.-J. Kim

P-31-007  The cortisol awakening response is restored after summer treatment programme in children with ADHD
Y. Yamashita, Japan
H. Okamura, C. Egami, S. Nagamitsu, T. Matsuishi, J. Furusyo, Y. Tada, A. Mukasa, C. Anai

P-31-008  The impact of EEG biofeedback for voluntary and involuntary movement of children with ADHD
E. Ziaikova, Slovakia
D. Bartko, S. Klobocka
P-31-009  Self-reported hyperactivity and conduct problems of adolescents in Prizren region, Kosovo
N. Fanaj, Albania
M. Gashi, G. Muja, I. Poniku

P-32-001  Can ADHD and externalizing disorders be helped in communities with no access to mental health care?
J. Fayyad, Lebanon
L. Farah, Y. Cassir, M. Salamoun, E. Karam

P-32-002  The efficacy of computerized working memory training on reducing comorbid psychiatric symptoms among prison inmates with Attention Deficit Hyperactivity Disorder
M. Hamzeloo, Iran
A. Mashhadi, J. Salehi Fadardi

P-32-003  Group Cognitive Behaviour Therapy (CBT) for adolescents and adults with Attention Deficit Hyperactivity Disorder (ADHD)
L. Hechtman, Canada
M. Mongia, M. Cherkasova

P-32-004  Dialectical behaviour therapy-based skills training in groups for adults with ADHD
T. Hirvikoski, Sweden
E. Morgensterns, J. Alfredsson, B. Bihlar Muld

P-32-005  Psychoeducative groups increases ADHD-knowledge and improves relationship quality in adults with ADHD and their significant others: An open feasibility study
T. Hirvikoski, Sweden
E. Waaler, E. von Heijne, M. Bygård, S. Bölte, J. Jokinen

P-32-006  Core exercise to decrease classroom off-task behaviour for university students
R. Kobayashi, Japan
S. Minami, K. Hirao

P-32-007  Cognitive behavioural therapy in medication and non-medication treated adults with Attention Deficit Hyperactivity Disorder: A systematic review
P. López, Argentina
D. Álvarez Prado, A. Lischinsky, F. Torrente

P-32-008  Neurofeedback of slow cortical potentials as a treatment for Adult Attention-Deficit / Hyperactivity Disorder (ADHD)
K. Mayer, Germany
S. Wyckoff, U. Strehl

P-32-009  Do Adults with ADHD exhibit specific (maladaptive) schemas?
P. Newark, Switzerland
E. Nyberg

P-33-001  Hyperactivity problems and peer victimisation among Nigerian school children
I. Adeosun, Nigeria
A. Adegbohun, O. Ogunlowo, A. Jejeloye, A. Pedro

P-33-002  The burden on caregivers of children with Attention Deficit Hyperactivity Disorder: The impact of psychiatric co-morbidity
I. Adeosun, Nigeria
A. Adegbohun, O. Fatiregun, O. Ogun

P-33-003  A comparison of sexually abused children with and without ADHD in South Korea
S. M. Bae, Republic of Korea
J. M. Kang, S. J. Moon, H. Baek
P-33-004 Missed ADHD amongst looked after children—does management in later stages help?
A. Band, United Kingdom
L. Murtaza, G. Kugan, P. Sahare, A. McMillan, C. Philipps

P-33-005 ADHD symptoms predict early math skills in preschool children
L. Guderjahn, Germany
A. Fäsch, C. Gunzenhauser, J. Merkt, A. von Suchodoletz, C. Gawrilow

P-33-006 In their own words: Characterizing the unmet needs of caregivers of children and adolescents with ADHD in Europe
E. Flood, USA
J. Quintero, V. Sikirica, P. Hodgkins, C. N. Dietrich, V. Harpin, K. Skodzki, K. Beusterien, M. H. Erder

P-33-007 Korean elementary school teachers’ perception and belief regarding children with ADHD: From a cultural psychological perspective
Y. Lee, Germany
E. Witruk

P-33-008 Parenting of children with ADHD in South Korea: The role of socio-emotional development of children with ADHD
W.-O. Oh, Republic of Korea
D.-H. Song

P-33-010 A community-based study of six to eight year old children with ADHD: Baseline data from the children’s attention project
E. Sciberras, Australia

P-33-011 Symptoms of inattention and hyperactivity/impulsivity in children in relation to parenting practices and parental self-efficacy
M. Swiecicka, Poland
M. Wozniak-Prus

P-33-012 Parenting style in children with ADHD compared to normal children
M. Firouzkouhi Moghaddam, Iran
A. Heidaripoor, I. arefi

P-34 Guided Poster Tours
15:00 – 16:00 Poster Exhibition Hall B
Life quality: Adults I
Chairperson: M. Danckaerts, Belgium

P-34-001 Functional impairments and risky behaviour among adults with ADHD in Europe, Japan, Australia and the United States
S. Able, USA
V. Haynes, J. Vietri, L. Kopenhafer, D. Novick, H. Upadhyaya, W. Deberdt

P-34-002 ADHD among adults in select countries from Europe: An analysis of online survey data
S. Able, USA
V. Haynes, J. Vietri, L. Kopenhafer, D. Novick, H. Upadhyaya, W. Deberdt

P-34-003 Sleepiness and driving performance in adults with ADHD
S. Bioulac, France
A. Capelli, A. Clarlet, J. Taillard, J. Rénéric, M. Bouvard, P. Philip

P-34-004 Managing ADHD in adulthood
M. Bjerrum, Denmark
P. Larsen, P. U. Pedersen

P-34-005 Combining qualitative and quantitative data to support the enduring development of executive function skills in students receiving supplementary special education funding
J. Brayley, Canada
P-34-006 Community workshops on ADHD improve ADHD knowledge and help-seeking behaviour
S. Burey, Canada
T. Burey

P-34-007 The relationship between attention and creativity in a cross-section of British adults
L. Carruthers, United Kingdom
A. Willis, R. MacLean

P-34-008 WHAAM: Web health application for ADHD monitoring
A. Chifari, Italy
M. Sanches-Ferreira, G. Doherty, P. Bamidis, A. Bilbow, R. Rinaldi

P-34-009 A comparison between life quality and weight-height measurements of patients, under stimulant and non-stimulant treatment due to Attention-Deficit and Hyperactivity Disorder and healthy population
M. Cikili Uytun, Turkey
E. Demirci, A. Kara, D. B. Öztop

P-34-010 Anxiety comorbidity in ADHD and its influence on quality of life
C. K. Gurkan, Turkey
E. Yurumez, F. H. Yaylıali, E. Aktas, Ö. F. Akça, F. A. Aysev

P-34-011 Economic burden of Attention Deficit Hyperactivity Disorder (ADHD): A European perspective of societal costs associated with childhood/adolescent ADHD
P. Hodgkins, USA
H. H. Le, M. Postma, J. Kahle, V. Sikirica, J. Setyawan, M. H. Erder, J. A. Doshi

P-35 Guided Poster Tours

15:00 – 16:00 Poster Exhibition Hall B

Life quality: Adults II
Chairperson: R.-D. Stieglitz, Switzerland

P-35-001 Childhood abuse and neglect in adult ADHD
U. Semiz, Turkey
O. Oner, F. Cengiz

P-35-002 A seven-year follow-up study of adult patients with ADHD: Preliminary results
R. Karam, Brazil

P-35-003 Effects of labelling and attributions on adolescent attitudes toward people with ADHD
C. Lara, Mexico
A. L. Balmaceda

P-35-004 Self-concept and academic achievement of elementary school students with ADHD symptoms
J. Merkt, Germany
J.-H. Ehm, M. Hasselhorn, C. Gawrilow

P-35-005 The executive and academic functioning of medicated and non-medicated adult college students with ADHD: A neuropsychological perspective
N. Nicholson, USA

P-35-006 Arithmetical difficulties in Attention Deficit Hyperactivity Disorder (ADHD) children: Clinical evaluation and stimulant response
A. Rezende, Brazil
J. Sergeant, S. Pacheco, S. Branco, U. Doria Filho, C. Boldrini, R. Fernandes, U. Reed, E. Casella
P-35-007  ADHD identity: A conceptual developmental model  
E. Schott, USA

P-35-009  Symptoms of Attention Deficit Hyperactivity Disorder and autism spectrum disorder as risk factors of psychosocial maladjustment in children and adolescents  
M. Tsujii, Japan

P-36-001  The association between cyber-victimization and Internet addiction of children and adolescents in Korea  
T. W. Park, Republic of Korea  
J.-C. Yang, Y.-C. Chung, S.-K. Chung, Y. S. Kim

P-36-002  Enhancing leadership capabilities towards effective ADHD management in Saudi Arabia: A challenge in paediatric practice  
S. Al-Yamani, Saudi Arabia

P-36-003  The prince who gave up the throne, did he have ADHD?  
G. H. Bahn, Republic of Korea  
M. Hong, Y. J. Lee

P-36-004  Subjective well-being and psychological well-being in secondary school students  
P. Coração, Portugal  
P. I. Santos, C. Sousa

P-36-005  Self-poisoning with drugs in Bamako  
H. Hami, Morocco  
T. Diallo, A. Maïga, A. Mokhtari, R. Soulaymani-Bencheikh, A. Soulaymani

P-36-006  “Uninhibited Imaginations” – Relation of impulsivity and creativity in college students  
J. Merkt, Germany  

P-36-007  Core symptoms, emotional dysregulation and functional impairment in adults with Attention Deficit Hyperactivity Disorder  
B. Mörstedt, Switzerland  
S. Corbisiero, R.-D. Stieglitz

P-36-008  Prevalence and comorbidity of ADHD in a historical cohort (1934-1970) in Madrid (Spain)  
A. Pelaz, Spain  
M. De los Reyes, R. Camameiro, S. Rodriguez, A. J. Heras, P. Rodriguez Ramos

P-36-009  Training needs analysis and the effectiveness of multidisciplinary ADHD training  
K. Puvanendran, United Kingdom  
M. Nagaraj, W. Walker

P-36-010  Evaluation of impact of ADHD training on education staff and service needs assessment  
K. Puvanendran, United Kingdom  
M. Nagaraj, W. Walker

P-36-011  The impact of methylphenidate and its enantiomers on the dopaminergic synthesis and metabolism in vitro  
J. Bartl, Switzerland  
E. Grünblatt, R. Schmidt, S. Walitza

P-36-012  Polyunsaturated fatty acids and the combination of iron zink and vitamin-B5 on neuronal cell line growth  
E. Grünblatt, Switzerland  
J. Bartl, B. Birtoli, S. Walitza, C. Terreux
**Guided Poster Tours**

15:00–16:00  
Poster Exhibition Hall B

**Miscellaneous II**
Chairperson: K. W. Lange, Germany

**P-37-001**  
ADHD-like behaviours and epigenetic dysregulation in mice offspring sired by male mice exposed to ethanol in pre-mating periods  
C. S. Choi, Republic of Korea  

**P-37-002**  
Death anxiety and the sense of symbolic immortality: The role of religion in a sample of the Portuguese working population  
P. I. Santos, Portugal  
O. Carvalho, V. Teixeira

**P-37-003**  
Symbolic immortality and familial amyloidotic polyneuropathy  
P. I. Santos, Portugal  
M. Oliveira, O. Carvalho

**P-37-004**  
Knowledge and misperceptions about Attention Deficit Hyperactivity Disorder of schoolteachers in Mumbai  
S. Sawant, India  
A. Prabhudesai

**P-37-005**  
Attention Deficit Hyperactivity Disorder: Are all the costs, benefits and outcomes being captured in economic evaluations?  
T. Soroncz-Szabo, Hungary  

**P-37-006**  
Service users experience of a national adult ADHD service  
S. Whitwell, United Kingdom  
S. Maltezos, M. Pitts, N. Gillan

**P-37-008**  
Survey of young people 11 years and above referred to an UK community paediatric child development centre with suspected ADHD-the need for clear ADHD pathways from primary care to specialist CAMHS and community paediatrics  
S. Yarney, United Kingdom  
V. Tyagi

**P-37-009**  
Roles of N-methyl-d-aspartate receptor and protein kinase B/glycogen synthase kinase-3β signalling in the paradoxical calming effect of amphetamine in a mouse model of Attention Deficit Hyperactivity Disorder  
Y.-C. Yen, Germany  
N. Gassen, T. Rein, C. Wotjak, E. Anderzhanova

**HT-11**  
Hot Topic Symposium

16:30–18:00  
Red

**Approaches to ADHD treatment**
Chairpersons: T. Banaschewski, Germany  
E. J. S. Sonuga-Barke, United Kingdom

**HT-11-001**  
Complementary and alternative treatments for ADHD: State of the evidence and practical implications  
L. E. Arnold, USA

**HT-11-002**  
The efficacy of psychological treatments for ADHD: Current evidence and future potential  
E. J. S. Sonuga-Barke, United Kingdom

**HT-11-003**  
Meta-analyses of pharmacological treatment  
T. Banaschewski, Germany
**HT-12**  Hot Topic Symposium

16:30 – 18:00  Yellow 1

The role of ADHD in forensic psychiatry
Chairpersons: M. Rösler, Germany  
S. Young, United Kingdom

**HT-12-001**  Prevalence of ADHD in prison and forensic psychiatric populations
M. Rösler, Germany

**HT-12-002**  Impact of ADHD on different types of criminal behaviour
W. Retz, Germany

**HT-12-003**  Critical incidents during imprisonment: Impact of ADHD
G. Gudjonsson, United Kingdom

**HT-12-004**  Medication for ADHD and criminality
H. Larsson, Sweden

---

**HT-14**  Hot Topic Symposium

16:30 – 18:00  Yellow 3

The relevance of iron in the pathogenesis of ADHD
Chairpersons: S. Cortese, Italy  
P. Riederer, Germany

**HT-14-001**  Iron in brain function
P. Riederer, Germany

**HT-14-002**  ADHD, Tourette’s syndrome and restless legs syndrome: The iron hypothesis
S. Cortese, Italy

**HT-14-003**  The relevance of iron in the pathogenesis of ADHD
M. Romanos, Germany

---

**HT-13**  Hot Topic Symposium

16:30 – 18:00  Yellow 2

ADHD research in Italy
Chairpersons: L. A. Rohde, Brazil  
A. Zuddas, Italy

**HT-13-001**  Biomarkers identification in ADHD
C. Scassellati, Italy  
C. Bonvicini, S. V. Faroene, M. Gennarelli

**HT-13-002**  Social responsiveness and deficits in facial emotion identification in ADHD
S. Carucci, Italy  
C. Peddis, L. Anchisi, A. Zuddas

**HT-13-003**  Impusivity, attentional saliency and decision making in adult with ADHD compared to pathological gamblers and obsessive compulsive patients
S. Pallanti, Italy  
G. Grassi, A. Cantisani, A. Grippa

**HT-13-004**  Dopamine transporter antibodies and ADHD
P. Curatolo, Italy

---

**HT-15**  Hot Topic Symposium

16:30 – 18:00  Blue 1

Brain mechanisms of ADHD interventions
Chairpersons: K. Rubia, United Kingdom  
P. Shaw, USA

**HT-15-001**  How ADHD pharmacological treatments impact in brain development?
P. Shaw, USA

**HT-15-002**  Differential response and mechanisms of action of stimulants and non-stimulants: findings from the USA
J. Newcorn, USA

**HT-15-003**  Differential mechanisms of action of stimulants and non-stimulants on ADHD brain function: Findings from the UK studies
K. Rubia, United Kingdom  
A. Cubillo, A. Smith, K. Chantiluke, H. Hart

**HT-15-004**  Brain mechanism of EEG neurofeedback
D. Brandeis, Germany
### HT-16 Hot Topic Symposium

**16:30 – 18:00**  
Blue 2

**Is something lacking in the current definitions of adult ADHD**

Chairpersons: P. Asherson, United Kingdom  
A. Reif, Germany

#### HT-16-001 Emotional Symptoms as a defining symptom dimension in adult ADHD
F. Reimherr, USA

#### HT-16-002 Deficits of emotional and self regulation
P. Asherson, United Kingdom

#### HT-16-003 The contribution of Informants to the diagnosis of Attention Deficit Hyperactivity Disorder in adult patients
R. G. Klein, USA

#### HT-16-004 Differences and similarities between ADHD and bipolar disorders in adults
A. Reif, Germany

---

**Please visit the Technical Exhibition**

**Opening hours**

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday</td>
<td>6 June 2013</td>
<td>15:00 – 21:00</td>
</tr>
<tr>
<td>Friday</td>
<td>7 June 2013</td>
<td>09:00 – 18:00</td>
</tr>
<tr>
<td>Saturday</td>
<td>8 June 2013</td>
<td>09:00 – 18:00</td>
</tr>
<tr>
<td>Sunday</td>
<td>9 June 2013</td>
<td>09:00 – 13:00</td>
</tr>
<tr>
<td>Session Code</td>
<td>Event Type</td>
<td>Time</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>ES-07</td>
<td>Educational Seminars</td>
<td>07:45 – 08:30</td>
</tr>
<tr>
<td>ES-08</td>
<td>Educational Seminars</td>
<td>07:45 – 08:30</td>
</tr>
<tr>
<td>ES-09</td>
<td>Educational Seminars</td>
<td>07:45 – 08:30</td>
</tr>
<tr>
<td>ES-10</td>
<td>Educational Seminars</td>
<td>07:45 – 08:30</td>
</tr>
<tr>
<td>ES-11</td>
<td>Educational Seminars</td>
<td>07:45 – 08:30</td>
</tr>
<tr>
<td>ES-12</td>
<td>Educational Seminars</td>
<td>07:45 – 08:30</td>
</tr>
<tr>
<td>PL-04</td>
<td>Plenary Sessions</td>
<td>08:30 – 10:30</td>
</tr>
<tr>
<td>PL-04-001</td>
<td>New pharmacological treatment options</td>
<td></td>
</tr>
<tr>
<td>PL-04-002</td>
<td>Cardiovascular safety of psychostimulants</td>
<td></td>
</tr>
<tr>
<td>PL-04-003</td>
<td>Non-pharmacological treatment</td>
<td></td>
</tr>
<tr>
<td>PL-04-004</td>
<td>Cost effectiveness of treatment</td>
<td></td>
</tr>
<tr>
<td>PL-05</td>
<td>Plenary Sessions</td>
<td>11:00 – 12:30</td>
</tr>
<tr>
<td>PL-05-001</td>
<td>Substance addiction in relation to ADHD; motivation and reward</td>
<td></td>
</tr>
<tr>
<td>PL-05-002</td>
<td>Neurophysiology of reward processing in ADHD</td>
<td></td>
</tr>
<tr>
<td>PL-05-003</td>
<td>Obesity</td>
<td></td>
</tr>
<tr>
<td>Closing Ceremony</td>
<td></td>
<td>12:30 – 13:00</td>
</tr>
</tbody>
</table>

Registration fee for Educational Seminars and Meet the Experts, per session: EUR 30.
Only valid in combination with the congress registration fee.
FRIDAY, 7 JUNE 2013

ES-01  Educational Seminars
07:45–08:30  Red

Organisation and carrying out of parent training in ADHD and OCD
Chairperson: C. Neuhaus, Germany

Purpose of the seminar: Improving the communication-strategies in families with ADHD.

Description of the seminar content: Kids with ADHD have at least one parent, who has ADHD as well (and knows the effect of negative communication: One fails to react as one wants or should do). Parents should know very well the functioning of the brain, as people with ADHD are at the mercy of their emotion... It requires a therapist with profound knowledge about ADHD as well in childhood, during adolescence and in adulthood with all comorbidities. If parents really understand this specific dysregulation of emotion, motivation and self-discipline they can develop a positive attitude towards the “special” style of perception and reaction in the family, talking without nagging, announcing every task friendly, reacting supportive (incl. learning to analyze conflicts and coping with self-management deficits). If it is understood, that the child doesn’t want to react inadequate, suffers from it´s faults (as does the parent!) and parents are prepared that “surprises” may happen every minute a day, they can react promptly, but relaxed, able to reinforce immediately the next positive behavior. It´s proven in clinical practice that punishment or negative consequences worsen the interaction and self-esteem. Literature: Neuhaus/Trott/Berger-Eckert/Schwab/Townson (2009) - Neuropsychotherapie der ADHS – Das Elterntraining für Kinder und Jugendliche (ETKJ ADHS) unter Berücksichtigung des selbst betroffenen Elternteils, Kohlhammer Verlag

Audience to be addressed: Healthcare professional interested to get an overview in ADHD-specific parent training.

ES-03  Educational Seminars
07:45–08:30  Blue 1

How to do best medication in adult ADHD?
Chairpersons: P. Mattos, Brazil
S. Pallanti, Italy

Abstract: ADHD pharmacological treatment in adulthood may be a challenge in clinical practice because of a myriad of comorbidities, degrees of impairment and phenotypic presentations.

Purpose of the seminar: To discuss how a phenotypically heterogeneous disorder like ADHD requires different approaches in pharmacological treatment

Description of the seminar content: Symptom severity X Degree of impairment. Context-dependent impairment. Individuals being treated since childhood X recently diagnosed in adulthood. Comorbidities and pharmacological treatment plan.

Audience to be addressed: Physicians

SATURDAY, 8 JUNE 2013

ES-04  Educational Seminars
07:45–08:30  Yellow 2

How to do neurofeedback in ADHD?
Chairpersons: P. Siegel-Gradenwitz, United Kingdom
U. Strehl, Germany

ES-05  Educational Seminars
07:45–08:30  Yellow 3

Comorbid disorders or attention-deficit-spectrum disorders?
Chairpersons: C. Freitag, Germany
C. Kieling, Brazil

Purpose of the seminar: Many children who later receive a diagnosis of Asperger Syndrome are first diagnosed with ADHD. In addition, a high rate of comorbidity does
exist especially between ADHD and atypical autism. In children with ADHD, an increased rate of ASD symptoms has been reported, even without an additional diagnosis of an autism spectrum disorder (ASD). These findings show that the clinical phenotype of ADHD and high-functioning ASD strongly overlap. As therapy for both disorders considerably differs, it is of strong clinical relevance to correctly diagnose children suspect of ADHD and/or ASD. The proposed educational session will give an overview on studies on autistic symptoms in children with ADHD and will discuss, if and when an additional ASD diagnosis should be given in children with ADHD. It also presents criteria for an ADHD diagnosis only despite some autistic traits in these children. Vice versa, ADHD traits (especially inattention) are common in children with high-functioning ASD. Studies on rates of comorbidity of ASD and ADHD are presented, and again, clinical criteria for a comorbid or differential diagnosis are discussed.

**Description of the seminar content:** The proposed educational session will give an overview on studies on autistic symptoms in children with ADHD and will discuss, if and when an additional ASD diagnosis should be given in children with ADHD. It also presents criteria for an ADHD diagnosis only despite some autistic traits in these children. Vice versa, ADHD traits (especially inattention) are common in children with high-functioning ASD. Studies on rates of comorbidity of ASD and ADHD are presented, and again, clinical criteria for a comorbid or differential diagnosis are discussed.

**Audience to be addressed:** Clinicians and researchers from the field of child and adolescent psychiatry, paediatric neurology or paediatrics, clinical psychologists.

**ES-06 Educational Seminars**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Seminar Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45–08:30</td>
<td>Blue 1</td>
<td>Assessment of adult ADHD</td>
</tr>
</tbody>
</table>

**Purpose of the seminar:** We have published studies showing that adult patients with ADHD may be divided into subtypes based on the presence of emotional and oppositional symptoms. In addition, the presence of personality traits and disorder significantly impacts the clinical presentation and treatment outcomes of adults with ADHD.
Non-pharmacologic treatment of ADHD in children and adolescents
Chairpersons: T. Jans, Germany
M. Aebi, Switzerland

Expert: T. Jans, Germany
Purpose of the seminar: Treatment of ADHD in children and adolescents comprises a multimodal approach including medication, various types of psychotherapy, education or training, or a combination of treatments. This educational seminar gives a brief overview on evidence based psychosocial interventions for ADHD in children and adolescents. There will be a focus on cognitive-behavioral interventions. Two treatment approaches will be described in more detail.

Description of the seminar content: Focus will be on behavioral parent-child training and on a cognitive behavioral treatment program ("Baghira Training") for 8- to 13-year old children with oppositional-defiant disorder (ODD). Behavioral parent-child training addresses dysfunctional parenting strategies which are regularly seen in parents of children with externalizing disorders. During parent training, parents learn to understand their child’s problem behavior. Major treatment steps comprise strategies to enhance parent-child relationships, setting educational goals, giving commands effectively, the use of praise, and applying operant interventions (e.g. time out, token economies, response cost). Self-management strategies for the child are developed. “Baghira Training” addresses ODD, which is a common co-morbid condition in children and adolescents with ADHD. The aims of the training are to increase the child’s social and communicational skills as well as to improve his/her emotional competences, anger control and problem and conflict solving skills using photos for discussion, role play, verbal and material rehearsal and home assignments. A special focus is given to treat ODD-irritable, ODD-headstrong and ODD-hurtful behaviors. In combination with other interventions such parent training and/or family therapy, the “Baghira Training” is a useful approach for children with ODD. Participants of this seminar will learn new skills and effective strategies for the treatment of externalizing disorders.

Audience to be addressed: The educational seminar addresses members of different professions who are involved in assessment, treatment and education of children and adolescents with ADHD (e.g. physicians, psychologists, pedagogues, and educators).

Expert: M. Aebi, Switzerland
Purpose of the seminar: Two non-pharmacological interventions with children suffering from ADHD and/or ODD will be presented. 1)… 2) The “Baghira Training”, a cognitive behavioural treatment (CBT) program for 8- to 13-years old children with ODD aged, is based on a standardised manual and encompasses nine weekly sessions of 120 minutes with groups of three to six children.

Description of the seminar content: An overview of the “Baghira Training” will be given and some specific therapeutic interventions will be demonstrated. The aims of the “Baghira Training” are to increase the child’s social and communicational skills as well as to improve his/her emotional competences, anger control and problem and conflict solving skills using photos for discussion, role play, verbal and material rehearsal and home assignments. A special focus is given to treat ODD-irritable, ODD-headstrong and ODD-hurtful behaviours. In combination with other interventions such parent training and/or family therapy, the “Baghira Training” is a useful approach for children with ODD. Participants of this seminar will learn new skills and effective strategies for the treatment of children with ODD.

Audience to be addressed: Child- and adolescent psychiatrists, child- and adolescent psychologists, and participants from allied disciplines, who wants to enhance their practical knowledge on CBT with children referred for ADHD/ODD.
EDUCATIONAL GOALS

### ES-08  Educational Seminars

**07:45 – 08:30  Yellow 1**

**Therapy of co-morbid disorders in adult ADHD**  
Chairperson:  J. Krause, Germany

**Purpose of the seminar:** The treatment of co-morbid disorders in adult ADHD is often complicated and requires sophisticated treatment strategies.

**Description of the seminar content:** This educational seminar discusses treatment strategies for adult ADHD with co-morbid depressive disorders, substance use disorders, anxiety disorders, bipolar disorders and autism with focus on pharmacological interventions.

**Audience to be addressed:** The participants should have experience in the field of pharmacological treatment of ADHD in adults.

### ES-09  Educational Seminars

**07:45 – 08:30  Yellow 2**

**How can I easily get update information on ADHD from the literature?**  
Chairpersons:  C. Maia, Brazil  
J. Fayyad, Lebanon

**Purpose of the seminar:** To help mental health professionals to keep themselves updated on valid and reliable scientific information on ADHD from the World Wide Web taking advantage of easy-to-use tools.

**Description of the seminar content:** The two presenters will: 1) show and discuss critically pros and cons of the available tools for extracting scientific information on ADHD from the Web; 2) demonstrate how to configure the most used and reliable databases to regularly provide information on ADHD from international literature; 3) teach how to extract useful information from the Google Scholar; 4) demonstrate how to set journals of interest to inform periodically the newest table of contents, and what is coming out (ahead of print); 5) indicate how to obtain full texts of interest from the Internet; 6) finally discuss some tips for organizing what is collected, and to avoid duplicate information.

**Audience to be addressed:** Mental health professionals, clinicians and young researchers who need/want to be regularly updated on everything published on ADHD.

### ES-10  Educational Seminars

**07:45 – 08:30  Yellow 3**

**Non-pharmacological treatment of ADHD in adults**  
Chairpersons:  A. Philipsen, Germany  
S. Young, United Kingdom

**Purpose of the seminar:** Adult ADHD is a serious risk factor for co-occurring psychiatric disorders and negative psychosocial consequences. Given this background, in addition to psychopharmacological treatment or instead of, there is a need for effective non pharmacological-treatment options for adults with ADHD.

**Description of the seminar content:** In the seminar two psychotherapy programmes developed and tested for the particular needs of adult ADHD patients are presented: (1) the dialectical behavioural treatment (DBT) based programme of the Freiburg Study Group (Philipsen et al.) and (2) the R&R2 for ADHD Youths and Adults (Young & Ross, 2007).

**Audience to be addressed:** Healthcare practitioners and allied professionals, trainees and students. ADHD treatment team members, researchers interested in psychotherapeutic treatment and evaluation.

**References:**  
http://dx.doi.org/10.1186/1471-244X-11-116  
**Purpose of the seminar:** To Give an Overview about an ADHD specific Coaching Approach.

**Description of the seminar content:** Adult ADHD patients often get a good understanding of disease mechanisms and coping strategies. However, they often find it difficult to transfer insights from therapy into daily routine. Here coaching offers a complementary technique. It encompasses an individual problem analysis and interventional strategies, eventually supported by the coach in the personal environment of the patient. Coaching involves management training techniques as well as specific cognitive behaviour therapy. It requires a trained coach with profound knowledge about adult ADHD and its specific problems. As such, coaching transfers experiences and represents an interface from clinical practice to daily routine, targeting a behavioural change in ADHD patients in terms of self discipline, self motivation, and emotional control.

**Audience to be addressed:** Healthcare Professionals interested to get an overview about an ADHD specific Coaching Approach.

**Purpose of the seminar:** There seems to be a small but severely ill subgroup of multiple media users with comorbidity and multiple risk factors that develop pervasive social isolation, increase of dosage craving and other features of addiction. This is important in particular for ADHD-patients, because their core symptoms are excessively rewarded by several internet and media-applications and they are attracted by these phenomena.

**Description of the seminar content:** In this seminar recent diagnostic and therapeutic concepts will be discussed in order to encourage ADHD-therapists to recognize PIU as a major problem in an increasing subgroup of ADHD-patients. Using the clinical diagnosis PIU, offering a comorbidity-oriented out- and in-patient approach with counselling of parents and teachers and treating them in a three-step-program seem to be a beginning in this field.

**Audience to be addressed:** This seminar is directed to clinicians as well as researchers who are interested in the impact of new (social) media on their ADHD-patients and their families. No previous knowledge is needed.
SATellite SymPosIA

FRIDAY, 7 JUNE 2013

**SA-01 Industry Supported Symposia**

*12:45 – 14:45 Auditorium Southwing*

Elvanse (lisdexamfetamine dimesylate): A new option in ADHD treatment

**Interactive Session** (Lunch to be provided)

D. Coghill, United Kingdom
R. Jain, USA
S. Chang, Canada
G. Polanczyk, Brazil
E. Cardo, Spain

Organizer: Shire

SATUrDAY, 8 JUNE 2013

**SA-02 Industry Supported Symposia**

*12:45 – 13:45 Red*

Treatment of ADHD in children and adolescents: What does recent data tell us about Atomoxetine?

Chairperson: S. Kasper, Austria

**SA-02-01** Systematic review of recent efficacy and safety data in children and adolescents

D. Coghill, United Kingdom

**SA-02-02** Setting the right expectations for our patients: How to use Atomoxetine?

F. Caby, Germany

Organizer: Eli Lilly and Company

**SA-03 Industry Supported Symposia**

*14:00 – 15:00 Yellow 1*

ADHD: Continuity and consistency of care

**SA-03-01** Childhood-onset ADHD: Consequences and burden of illness

P. Asherson, United Kingdom

**SA-03-02** Transition from childhood: ADHD presentation and management

I. Manor, Israel

**SA-03-03** Evidence-based treatment: The need for continuing care

M. Huss, Germany

Organizer: Novartis Pharma AG
CPO HANSER SERVICE is specialist in the field of Conference, Event, Destination and Association Management organizing events of any size throughout Germany and also abroad for more than 30 years.

We organize your success

CPO HANSER SERVICE

CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT

We offer you:

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- inhouse graphic design
- association management

BERLIN
Paulsborner Straße 44
14193 Berlin
fon +49-30-300 669 0
fax +49-30-305 73 91
Email: berlin@cpo-hanser.de

HAMBURG
Zum Ehrenhain 34
22885 Barsbüttel
fon +49-40-670 882 0
fax +49-40-670 32 83
Email: hamburg@cpo-hanser.de

FRANKFURT
Julius-Reiber-Strasse 15a
64293 Darmstadt
fon: +49-6151-428 368 0
fax: +49-6151-428 368 9
Email: frankfurt@cpo-hanser.de

www.cpo-hanser.de
## LIST OF EXHIBITORS AND MAP

The organizers gratefully acknowledge the support of the following companies and associations (as per May 2013).

### Company | Booth No. | Company | Booth No.
---|---|---|---
**Principal Sponsor**
Shire | 4 / 5 | ADHD Europe/A.I.F.A. Onlus | 9
**Major Sponsor**
Eli Lilly and Company | 1 | World Federation of ADHD | 7
**General Exhibitors**
MEDICE Arzneimittel Pütter GmbH & Co. KG | 3 | CINP – Collegium International Neuro-Psychopharmacologicum | 11
SensoDetect AB (publ) | 8 | DGPPN – Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde | 12
Vifor Pharma | 2 | ECSR Congress 2013 in Berlin | 14
Wisepress Ltd | 6 | Springer WienNewYork | 13
ADHD Europe/A.I.F.A. Onlus | 9 | WFSBP – World Federation of Societies of Biological Psychiatry | 10
World Federation of ADHD | 7 | CINP – Collegium International Neuro-Psychopharmacologicum | 11
DGPPN – Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde | 12 | ECSR Congress 2013 in Berlin | 14
Springer WienNewYork | 13 | WFSBP – World Federation of Societies of Biological Psychiatry | 10
CINP – Collegium International Neuro-Psychopharmacologicum | 11 | ECSR Congress 2013 in Berlin | 14
WFSBP – World Federation of Societies of Biological Psychiatry | 10

### EXHIBITION MAP – HALL B, 1ST FLOOR

![Exhibition Map](image-url)
LIST OF CHAIRPERSONS AND PRESENTERS

A
Able, S. ..................................... 48
Abuzzahab, F. ............................. 44
Adamou, M. ............................... 23
Adeosun, I. ................................. 26, 47
Aebi, M. ................................... 54, 57
Aguirar, I. .................................. 45
Ahlers, E. .................................. 26
Alfaiaite, C. ............................... 35
Al-Yamani, S. ............................. 50
Araujo, E. .................................. 35
Arnold, L. E. .............................. 40, 51
Arns, M. .................................. 37
Asherson, P. .............................. 44, 53, 60
Ayres, E. ................................. 42
Azevedo, A. ............................... 46
Azzam, H. ................................. 33

B
Bae, S. M. .................................. 47
Bahn, G. H. ............................... 50
Baijot, S. ................................. 22
Balseviciene, B. .......................... 25
Banaschewski, T. ...................... 40, 51
Band, A. ................................... 48
Bandeira de Lima, C. ............... 38
Barel, E. ................................... 46
Barkley, R. A. ............................ 23, 28
Barragan, E. ............................. 34
Bartl, J. .................................... 26
Basoglu, C. .............................. 30
Battle Vila, S. ........................... 42
Baur, R. .................................... 35
Benamor, L. .............................. 41
Bergh, R. .................................. 41
Bianchi, V. ............................... 32
Biederman, J. ......................... 38, 42
Bihlar Muld, B. ......................... 29
Bijlenga, D. ............................... 29
Bikic, A. .................................. 45
Bikke-Hentsch, O. .................... 41, 54, 59
Blakely, T. ............................... 24
Biouacic, S. .............................. 24, 48
Biscaldi, M. ............................... 38
Bjerrum, M. .............................. 48
Boaiva, J. ................................. 41
Boilson de Araujo, G. .............. 30
Boilson, A. .............................. 28, 39
Bonath, B. ............................... 34
Bonnefois, G. ........................... 43
Brambilla, P. ............................. 45
Brandejs, D. ............................. 33, 52
Brayley, J. ............................... 48
Brons, A. ................................. 44
Bruxel, E. .................................. 32
Bueno, V. ................................. 40
Buitelaar, J. ............................ 21, 38, 45, 54
Burey, S. ................................. 49
Burke, A. ................................. 30
Buyck, I. .................................. 33

C
Caby, F. .................................. 60
Campradon, E. ......................... 35
Cardo, E. .................................. 60
Cardo Jalón, E. ......................... 23
Carruthers, L. ........................... 49
Carucchi, S. ............................. 52
Carvalhosa, C. ......................... 30
Castellanos, F. X. .................... 37, 38
Chang, S. ................................. 60
Chasqueira, C. .......................... 24
Chifari, A. ............................... 49
Choi, C. S. ............................... 51
Cho, S.-C. ............................... 22
Chronaki, G. ............................ 33
Cikili Uytun, M. ...................... 49
Ciuluvica, C. ............................ 35
Coelho, L. F. ............................ 46
Coghill, D. .............................. 38, 60
Colomer, C. ............................. 26, 40
Conzelmann, A. ..................... 33
Coogan, A. .............................. 36, 39
Corazhán, P. ............................ 50
Corbíserio, S. ........................... 40
Cortese, S. .............................. 30, 52
Costa, D. ................................. 30
Crippa, A. ............................... 30, 36
Curatolo, P. ............................. 52

D
Dabkowska, M. ......................... 30, 34, 36
D’Amelio, R. ............................ 54, 59
Dancakerts, M. ....................... 36, 48
Darini, M. .............................. 44
De Brito, S. ............................ 22
Denda, K. ............................... 25
Den Heijer, A. ......................... 41
Dittmann, R. ............................ 41
Durão, F. ................................. 25

E
Edbom, T. ............................... 29
Edge, A. ................................. 33
Elgen, S. ................................. 22
El Missiry, M. ......................... 28, 47
Ercan, E. S. ............................. 28, 45
Esposito, D. ............................ 30

F
Fallgatter, A. ............................ 54
Fallu, A. ................................. 24
Fanaj, N. ................................. 47
Fayyad, J. ............................... 47, 54, 58
Fieve, R. ................................. 41
Figaro, R. ............................... 36
Firoozkouhi Moghaddam, M. .... 31, 48
Flood, E. ................................. 48
Fossati, A. .............................. 26, 37
Franke, B. ............................... 21, 22, 32
Freitag, C. .............................. 38, 55
Fuchs, J. .................................. 37
Fuemaier, A. B. M. ................... 36, 40

G
Gabriel, A. ............................... 44
Garas, P. ................................. 26
Genizi, J. ................................ 28
Gerlach, M. ............................. 36, 38
Ghanizadeh, A. ...................... 41
Ghiasuddin, A. ....................... 28
Ghosh, M. ............................... 41
Ginsberg, Y. ............................ 44
Gonzalez Cantarero, V. .......... 30
Gonzalez, R. ............................ 27, 29
Greenhill, L. ......................... 23, 36, 41
Groen, Y. ............................... 27
Grünblatt, E. ........................... 50
Guderjahn, L. ........................... 48
Gudjonsson, G. ....................... 52
Gurkan, C. K. ......................... 49

H
Hach, I. ................................. 40
Halperin, J. ............................. 22
Hami, H. ................................. 50
Hamza, M. ............................... 30
Hamzeloo, M. ......................... 47
Han, D. H. ............................... 26
Harpire, V. ............................. 41
Hasan, A. ............................... 34
Hasler, R. ............................... 34
Haynes, V. ............................. 44
Hechtman, L. ......................... 33
### LIST OF CHAIRPERSONS AND PRESENTERS

<table>
<thead>
<tr>
<th>L</th>
<th>Lajic, A.</th>
<th>25</th>
</tr>
</thead>
<tbody>
<tr>
<td>L</td>
<td>Lambregts-Rommelse, N.</td>
<td>21</td>
</tr>
<tr>
<td>L</td>
<td>Lange, A.-M.</td>
<td>46</td>
</tr>
<tr>
<td>L</td>
<td>Lange, K. W.</td>
<td>22, 23, 36, 51</td>
</tr>
<tr>
<td>L</td>
<td>Lara, C.</td>
<td>28, 49</td>
</tr>
<tr>
<td>L</td>
<td>Larsson, H.</td>
<td>52</td>
</tr>
<tr>
<td>L</td>
<td>Lederer, A.</td>
<td>35</td>
</tr>
<tr>
<td>L</td>
<td>Lee, J. S.</td>
<td>42</td>
</tr>
<tr>
<td>L</td>
<td>Lee, X. Y.</td>
<td>46</td>
</tr>
<tr>
<td>L</td>
<td>Lee, Y.</td>
<td>48</td>
</tr>
<tr>
<td>L</td>
<td>Lee, Y. S.</td>
<td>25</td>
</tr>
<tr>
<td>L</td>
<td>Lerner, A.</td>
<td>27</td>
</tr>
<tr>
<td>L</td>
<td>Lesch, K.-P.</td>
<td>21, 23, 32</td>
</tr>
<tr>
<td>L</td>
<td>Liebrenz Rosenstock, M.</td>
<td>29</td>
</tr>
<tr>
<td>L</td>
<td>Li, H.</td>
<td>32</td>
</tr>
<tr>
<td>L</td>
<td>Lima Ladeira Colonelli, V. L.</td>
<td>28</td>
</tr>
<tr>
<td>L</td>
<td>Limbos, M.</td>
<td>24</td>
</tr>
<tr>
<td>L</td>
<td>Lim, C. G.</td>
<td>42</td>
</tr>
<tr>
<td>L</td>
<td>Lim, L.</td>
<td>22, 34</td>
</tr>
<tr>
<td>L</td>
<td>Linden, S.</td>
<td>42</td>
</tr>
<tr>
<td>L</td>
<td>Liu, L.</td>
<td>37</td>
</tr>
<tr>
<td>L</td>
<td>López, P.</td>
<td>47</td>
</tr>
<tr>
<td>L</td>
<td>Luccherino, L.</td>
<td>46</td>
</tr>
<tr>
<td>L</td>
<td>Lycett, K.</td>
<td>26</td>
</tr>
</tbody>
</table>

| M | Macek, J. | 24 |
| M | Mahone, M. | 35 |
| M | Maia, C. | 54, 58 |
| M | Maitra, S. | 32 |
| M | Manor, I. | 36, 60 |
| M | Mardomingo, M. J. | 28 |
| M | Marinoff, L. | 38 |
| M | Martsenkovsky, I. | 32 |
| M | Mateescu, L. | 36 |
| M | Mattos, P. | 23, 55 |
| M | Mayer, K. | 47 |
| M | Mayer Villa, P. | 26 |
| M | Mejvis, L. | 21 |
| M | Melegari, M. G. | 31 |
| M | Mello, C. | 35 |
| M | Merkt, J. | 49, 50 |
| M | Merwood, A. | 37 |
| M | Miano, S. | 37 |
| M | Miguel, C. S. | 30 |
| M | Miranda, M. | 27 |
| M | Mörsted, B. | 50 |
| M | Mowinckel, A. M. | 40 |
| M | Moya, J. | 35 |

| N | Mukhopadhyay, K. | 33 |
| N | Mutlu, C. | 31 |

| O | Naidoo, K. | 44 |
| O | Nakai, A. | 28 |
| O | Neuhaus, C. | 23, 55 |
| O | Newark, P. | 47 |
| O | Newcorn, J. | 52 |
| O | Ng, J. | 26 |
| O | Nicholson, N. | 49 |
| O | Nieweg, E. | 38 |

| P | Oguni, M. | 28 |
| P | Oh, W.-O. | 48 |
| P | Onuc, B. | 30, 44 |
| P | Ong, M. Y. | 26 |
| P | Ortiz, S. | 26 |
| P | Orla, A. | 27 |

| Q | Palacios Cruz, L. | 33 |
| Q | Pallanti, S. | 23, 52, 54, 55 |
| Q | Palma, S. M. | 27, 42 |

| R | Panagiotidis, M. | 40 |
| R | Pan, D. | 46 |
| R | Park, E. J. | 34 |
| R | Park, T. W. | 24, 50 |
| R | Pastura, G. | 37 |
| R | Pedersen, M. L. | 40 |
| R | Pelaz, A. | 50 |
| R | Pelletier, M.-F. | 40 |
| R | Pereira, N. | 46 |
| R | Philipson, A. | 21, 46, 54, 58 |
| R | Polanczyk, G. | 22, 23, 50, 55, 60 |
| R | Polina, E. R. | 33 |
| R | Pollak, Y. | 27 |
| R | Puvanendran, K. | 50 |

<p>| K | Kang, H. | 45 |
| K | Kang, J. | 32, 45 |
| K | Kao, C.-C. | 27 |
| K | Karam, R. | 49 |
| K | Kasper, S. | 60 |
| K | Kayser, C. | 26 |
| K | Kesic, A. | 42 |
| K | Kieling, C. | 26, 38, 55 |
| K | Kive, E. | 32 |
| K | Kim, B.-N. | 32 |
| K | Kim, J.-H. | 27 |
| K | Kittel-Schneider, S. | 37 |
| K | Klein, R. G. | 23, 40, 53, 54 |
| K | Kobayashi, R. | 47 |
| K | Konstenius, M. | 21 |
| K | Kooij, S. | 54 |
| K | Krause, J. | 54, 58 |
| K | Kumar, V. | 45 |
| K | Kwak, Y. | 29 |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rutterford, N.</td>
<td>25</td>
</tr>
<tr>
<td>Rubio Morell, B.</td>
<td>42</td>
</tr>
<tr>
<td>Rubia, K.</td>
<td>34, 52</td>
</tr>
<tr>
<td>Romanos, M.</td>
<td>35, 37, 52</td>
</tr>
<tr>
<td>Rösler, M.</td>
<td>44, 52</td>
</tr>
<tr>
<td>Rohde, L. A.</td>
<td>22, 23, 38, 52</td>
</tr>
<tr>
<td>Romano, M.</td>
<td>35, 52</td>
</tr>
<tr>
<td>Rüba, K.</td>
<td>34, 52</td>
</tr>
<tr>
<td>Rubio Morell, B.</td>
<td>42</td>
</tr>
<tr>
<td>Rutterford, N.</td>
<td>25</td>
</tr>
<tr>
<td>Saha, T.</td>
<td>33</td>
</tr>
<tr>
<td>Saito, T.</td>
<td>22</td>
</tr>
<tr>
<td>Salatino de Oliveira, A.</td>
<td>33</td>
</tr>
<tr>
<td>Santinelli, L.</td>
<td>46</td>
</tr>
<tr>
<td>Santos, P. I.</td>
<td>51</td>
</tr>
<tr>
<td>Saville, C.</td>
<td>33, 34</td>
</tr>
<tr>
<td>Savant, S.</td>
<td>51</td>
</tr>
<tr>
<td>Scassellati, C.</td>
<td>52</td>
</tr>
<tr>
<td>Schlander, M.</td>
<td>23</td>
</tr>
<tr>
<td>Schmueser, L.</td>
<td>35</td>
</tr>
<tr>
<td>Schott, E.</td>
<td>50</td>
</tr>
<tr>
<td>Sciberras, E.</td>
<td>46, 48</td>
</tr>
<tr>
<td>Segal, Y.</td>
<td>24</td>
</tr>
<tr>
<td>Semiz, U.</td>
<td>49</td>
</tr>
<tr>
<td>Senol, V.</td>
<td>28</td>
</tr>
<tr>
<td>Septier, M.</td>
<td>35</td>
</tr>
<tr>
<td>Setyawan, J.</td>
<td>31, 43</td>
</tr>
<tr>
<td>Shaw, P.</td>
<td>35, 52</td>
</tr>
<tr>
<td>Shin, M.-S.</td>
<td>46</td>
</tr>
<tr>
<td>Shin, Y.</td>
<td>28</td>
</tr>
<tr>
<td>Shyu, L.-Y.</td>
<td>31</td>
</tr>
<tr>
<td>Sidlauskaite, J.</td>
<td>35</td>
</tr>
<tr>
<td>Siegel-Gradenwitz, P.</td>
<td>38, 55</td>
</tr>
<tr>
<td>Sikirica, V.</td>
<td>43</td>
</tr>
<tr>
<td>Silva, D.</td>
<td>22, 47</td>
</tr>
<tr>
<td>Silva, K.</td>
<td>27</td>
</tr>
<tr>
<td>Skirrow, C.</td>
<td>33</td>
</tr>
<tr>
<td>Skogli, E. W.</td>
<td>39</td>
</tr>
<tr>
<td>Slama, H.</td>
<td>35</td>
</tr>
<tr>
<td>Socanski, D.</td>
<td>26</td>
</tr>
<tr>
<td>Soloviev, A.</td>
<td>43</td>
</tr>
<tr>
<td>Sommer, O.</td>
<td>43</td>
</tr>
<tr>
<td>Song, D.-H.</td>
<td>43</td>
</tr>
<tr>
<td>Sonuga-Barke, E. J. S.</td>
<td>22, 51</td>
</tr>
<tr>
<td>Sorensen, L.</td>
<td>39</td>
</tr>
<tr>
<td>Soroncz-Szabo, T.</td>
<td>51</td>
</tr>
<tr>
<td>Soutullo, C.</td>
<td>43</td>
</tr>
<tr>
<td>Steinhausen, H.-C.</td>
<td>36</td>
</tr>
<tr>
<td>Stermat, T.</td>
<td>24</td>
</tr>
<tr>
<td>Stieglitz, R.-D.</td>
<td>36, 49</td>
</tr>
<tr>
<td>Štimac, D.</td>
<td>29</td>
</tr>
<tr>
<td>Stokbaek, N.</td>
<td>31</td>
</tr>
<tr>
<td>Strehl, U.</td>
<td>38, 55</td>
</tr>
<tr>
<td>Stuhc, M.</td>
<td>43</td>
</tr>
<tr>
<td>Surathi, P.</td>
<td>26</td>
</tr>
<tr>
<td>Suren, S.</td>
<td>33</td>
</tr>
<tr>
<td>Surman, C. B.</td>
<td>37</td>
</tr>
<tr>
<td>Su, Y.</td>
<td>43</td>
</tr>
<tr>
<td>Swiecicka, M.</td>
<td>48</td>
</tr>
<tr>
<td>Szpindel, I.</td>
<td>34</td>
</tr>
<tr>
<td>Tandon, M.</td>
<td>29</td>
</tr>
<tr>
<td>Tanju, I. A.</td>
<td>31</td>
</tr>
<tr>
<td>Tatiana, D.</td>
<td>27</td>
</tr>
<tr>
<td>Tebartz van Elst, L.</td>
<td>21, 27</td>
</tr>
<tr>
<td>Tegelbeckers, J.</td>
<td>35</td>
</tr>
<tr>
<td>Thorne, J.</td>
<td>24, 36, 38</td>
</tr>
<tr>
<td>Tillman, C.</td>
<td>39</td>
</tr>
<tr>
<td>Todd, G.</td>
<td>40</td>
</tr>
<tr>
<td>Torrente, F.</td>
<td>27</td>
</tr>
<tr>
<td>Trembach, A.</td>
<td>34</td>
</tr>
<tr>
<td>Treuer, T.</td>
<td>43</td>
</tr>
<tr>
<td>Trevisan, B.</td>
<td>24, 46</td>
</tr>
<tr>
<td>Tsai, C.-J.</td>
<td>29</td>
</tr>
<tr>
<td>Tsuji, M.</td>
<td>50</td>
</tr>
<tr>
<td>Tucha, O.</td>
<td>23, 36, 47</td>
</tr>
<tr>
<td>Upadhyaya, H.</td>
<td>43, 45</td>
</tr>
<tr>
<td>V</td>
<td>25</td>
</tr>
<tr>
<td>Vaithiyam, A.</td>
<td>26</td>
</tr>
<tr>
<td>Valagussa, S.</td>
<td>39</td>
</tr>
<tr>
<td>van Cauwenberge, V.</td>
<td>39</td>
</tr>
<tr>
<td>Vance, A.</td>
<td>25</td>
</tr>
<tr>
<td>van de Giind, G.</td>
<td>21, 29, 54</td>
</tr>
<tr>
<td>Vanicek, T.</td>
<td>25</td>
</tr>
<tr>
<td>Velez-Pastrana, M.</td>
<td>40</td>
</tr>
<tr>
<td>Victor, M.</td>
<td>44</td>
</tr>
<tr>
<td>Vingilis, E.</td>
<td>29</td>
</tr>
<tr>
<td>Visanuyothin, T.</td>
<td>29</td>
</tr>
<tr>
<td>Vogel, S.</td>
<td>44</td>
</tr>
<tr>
<td>Voinescu, B.</td>
<td>25</td>
</tr>
<tr>
<td>Volkmann, J.</td>
<td>21</td>
</tr>
<tr>
<td>W</td>
<td>22, 23, 25</td>
</tr>
<tr>
<td>Walitza, S.</td>
<td>22</td>
</tr>
<tr>
<td>Wang, Y.</td>
<td>22</td>
</tr>
<tr>
<td>Warnke, A.</td>
<td>21, 23</td>
</tr>
<tr>
<td>Weiler, L. J.</td>
<td>39</td>
</tr>
<tr>
<td>Weissbrodt, K.</td>
<td>27</td>
</tr>
<tr>
<td>Weiss, M.</td>
<td>23, 38, 54</td>
</tr>
<tr>
<td>Whitwell, S.</td>
<td>51</td>
</tr>
<tr>
<td>Willcut, E.</td>
<td>23, 28</td>
</tr>
<tr>
<td>Winterstein, A. G.</td>
<td>54</td>
</tr>
<tr>
<td>Wirth, A.</td>
<td>31</td>
</tr>
<tr>
<td>Wolters, E. C.</td>
<td>21</td>
</tr>
<tr>
<td>Y</td>
<td>43, 46</td>
</tr>
<tr>
<td>Yamashita, Y.</td>
<td>43, 46</td>
</tr>
<tr>
<td>Yarney, S.</td>
<td>51</td>
</tr>
<tr>
<td>Yen, Y.-C.</td>
<td>51</td>
</tr>
<tr>
<td>Younghui, Y.</td>
<td>39</td>
</tr>
<tr>
<td>Young, S.</td>
<td>52, 54, 58</td>
</tr>
<tr>
<td>Yulaf, Y.</td>
<td>31, 39</td>
</tr>
<tr>
<td>Yu, X.</td>
<td>39</td>
</tr>
<tr>
<td>Z</td>
<td>43, 45</td>
</tr>
<tr>
<td>Zelnik, N.</td>
<td>43</td>
</tr>
<tr>
<td>Zenglein, Y.</td>
<td>24</td>
</tr>
<tr>
<td>Ziakova, E.</td>
<td>46</td>
</tr>
<tr>
<td>Ziegler, S.</td>
<td>31, 45</td>
</tr>
<tr>
<td>Zuddas, A.</td>
<td>23, 43, 52, 54</td>
</tr>
</tbody>
</table>
A new option in ADHD treatment.

Shire Lunch Symposium.

ADHD is a diverse and multifaceted condition; different patients have different needs and different treatment goals and require an individualised approach to management.

This symposium will introduce a new option for the treatment of ADHD. The programme will include a series of presentations, panel discussions and the opportunity to interact with faculty.

We look forward to welcoming you to what we hope will be an informative and interactive session.

Please join us

Date:
Friday, 7th June 2013

Time:
12.45 to 14.45
Lunch will be served

Meeting room:
Auditorium, South Wing

FACULTY

Dr Esther Cardo
Neuropaediatrician
Hospital Son Llatzer Palma de Mallorca
Spain

Dr Sam Chang
Child and Adolescent Psychiatrist
Clinical Associated Professor
University of Calgary Faculty of Medicine
Canada

Dr David Coghill
Reader in Child and Adolescent Psychiatry
Ninewell’s Hospital and Medical School Dundee
United Kingdom

Dr Rakesh Jain
Associate Clinical Professor
Department of Psychiatry and Behavioral Sciences
University of Texas
USA

Dr Guilherme Polanczyk
Assistant Professor of Child and Adolescent Psychiatry
University of São Paulo
Brazil

Shire
Meeting organised and funded by Shire.

Symposium organised during the 4th World Congress on ADHD - Milan 2013

Item Code: INTSP/BH/ADHD/13/0057a
Date of Preparation: May 2013
CONGRESS AND EXHIBITION OFFICE

Hamburg Office
CPO HANSER SERVICE
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49-40-670 88 20
Fax: +49-40-670 32 83
Email: adhd2013@cpo-hanser.de

www.adhd-congress.org